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Anion Channel. Physiol Rev 99: 707–738, 2019. Published December 5, 2018;
doi:10.1152/physrev.00007.2018.—The cystic fibrosis transmembrane conduc-
tance regulator (CFTR) belongs to the ATP binding cassette (ABC) transporter super-
family but functions as an anion channel crucial for salt and water transport across
epithelial cells. CFTR dysfunction, because of mutations, causes cystic fibrosis (CF). The anion-
selective pore of the CFTR protein is formed by its two transmembrane domains (TMDs) and
regulated by its cytosolic domains: two nucleotide binding domains (NBDs) and a regulatory (R)
domain. Channel activation requires phosphorylation of the R domain by cAMP–dependent protein
kinase (PKA), and pore opening and closing (gating) of phosphorylated channels is driven by ATP
binding and hydrolysis at the NBDs. This review summarizes available information on structure and
mechanism of the CFTR protein, with a particular focus on atomic-level insight gained from recent
cryo-electron microscopic structures and on the molecular mechanisms of channel gating and its
regulation. The pharmacological mechanisms of small molecules targeting CFTR’s ion channel
function, aimed at treating patients suffering from CF and other diseases, are briefly discussed.
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I. INTRODUCTION
A. CFTR and Cystic Fibrosis
Cystic fibrosis (CF) is the most common life-threatening,
inherited monogenic disorder among Caucasian popula-
tions; it affects 1 in ~2500 newborns in Europe and 1 in
~3500 newborns in the United States. CF is a multiorgan
disorder, with symptoms including airway blockage by
thickenedmucus, leading to chronic lung infections, inflam-
mation and bronchiectasis, blockage of pancreatic ducts
and consequent pancreatic insufficiency, bowel obstruction
in newborns, male infertility because of obstruction of the
vas deferens, and a characteristic high-salt sweat diagnostic
of the disease. Although at present efficient causative treat-
ment is still restricted to a small subset of CF patients, in the
past decades, improvements in patient care and symptom-
atic treatment have greatly prolonged the life expectancy of
people born with CF, from ~1 yr in 1950 to ~40 yr at
present (171).
The primary defect in CF patients is a reduction in chloride
(190, 259) and bicarbonate (208) transport capacity across
the apical membrane of epithelial cells. In 1989, the gene
mutated in CF patients was identified on chromosome 7 by
positional cloning (201), and the protein product was
named the cystic fibrosis transmembrane conductance reg-
ulator (CFTR) to reflect its presumed involvement in the
regulation of other anion transport proteins. Purification of
the CFTR protein and its functional reconstitution in lipid
bilayers soon provided proof that CFTR is, itself, the anion
channel responsible for cAMP–dependent anion transport
across epithelial surfaces (16).
B. The ABC Protein Superfamily
CFTR is a member of the large superfamily of tens of thou-
sands of ATP binding cassette (ABC) proteins that are
found in all kingdoms of life (147) and that serve to trans-
port a large variety of substrates into and out of cells at the
expense of ATP hydrolysis. ABC proteins share a conserved
general architecture based on the modular assembly of four
canonical domains: two transmembrane domains (TMDs)
and two cytosolic nucleotide binding domains (NBDs). The
number of polypeptide chains that this “core” functional
unit comprises is variable. In prokaryotes, the four domains
are often expressed as four individual polypeptides or as
two TMD/NBD “half transporters” that coassemble post-
translationally. The human genome encodes 48 ABC pro-
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teins, which have been grouped into seven subfamilies
(ABCA–G) (69). Except for the E and F subfamilies, which
contain no TMDs, the human ABC proteins consist either
of half transporters that homo- or heterodimerize or of full
transporters in which the four canonical domains are linked
in a single polypeptide chain. The ABCC subfamily, to
which CFTR (ABCC7) belongs, falls into the latter class. In
CFTR, each TMD contains six transmembrane (TM) heli-
ces, and the two homologous TMD-NBD halves (TMD1-
NBD1 and TMD2-NBD2) are linked by a contiguous,
unique, cytosolic regulatory (R) domain (201) (FIGURE 1A).
At the sequence level, CFTR’s two homologous halves dis-
play a marked asymmetry, a general feature of ABCC sub-
family proteins (187). Within the entire ABC superfamily,
CFTR is the only protein shown to form a transmembrane
ion channel pore, in contrast to the vast majority of its
homologs that serve as active transporters. The only other
exceptions among human ABC proteins are the soluble E
and F subfamily members, that are not involved in trans-
membrane transport, and CFTR’s close relatives SUR1
(ABCC8) and SUR2 (ABCC9) that serve as regulatory sub-
units of ATP-sensitive potassium (KATP) channels (69).
C. Basic Functional Properties of the CFTR
Anion Channel
Opening and closing (gating) of the CFTR anion pore is
largely regulated by two processes. First, for a CFTR chan-
nel to become activated, its cytosolic R domain must be
phosphorylated by cAMP–dependent protein kinase (PKA)
(20, 48, 183, 225). Second, gating of a phosphorylated
CFTR channel is driven by binding of ATP to its cytosolic
NBDs (9). In single-channel recordings, CFTR channel ac-
tivity displays typical bursting behavior, with brief (in-
traburst) closures interrupting longer periods of channel
opening, yielding open bursts that are separated by long
(interburst) closures (32, 95, 261). Gating kinetics are rela-
tively slow; the duration of a burst and interburst cycle is on
a second timescale (0.1–2 s, depending on species, phos-
phorylation level, and temperature) rather than the milli-
second timescale of voltage-gated channels. Moreover, ex-
cept for the kinetics of intraburst closures, which little affect
channel open probability (30), CFTR gating is largely volt-
age independent (20). Anion permeation through the open
pore follows simple ohmic behavior: in symmetrical 140
mM of chloride, the unitary current/voltage relationship is
relatively linear (20, cf. Ref. 30) with a slope conductance of
~10 pS at 35–37°C (20) or ~7–8 pS at 20–25°C (227).
These basic biophysical properties serve as a fingerprint that
allows reliable identification of CFTR currents both in na-
tive tissues and in heterologous expression systems.
D. Root Cause of CF Disease Symptoms
To date, more than 2,000 CFTR mutations have been iden-
tified in CF patients (http://www.genet.sickkids.on.ca), a
remarkable number for a 1480-residue protein, although a
subset of these variations is likely to have no functional
consequence. The roughly 200mutations that are known to
cause CF are traditionally classified (68, 282) based on how
they affect the encoded protein, that is, whether they abol-
ish or reduce the production of the full-length CFTR poly-
peptide (truncation mutations, Class I; alternative splicing,
Class V), impair protein trafficking/maturation (Class II),
impair regulation of channel gating (Class III) or anion
permeation through the open channel pore (Class IV), or
affect the lifetime of the channel protein in the apical mem-
brane (Class VI). Despite the large number of identified
CFTR mutations, a single mutation, deletion of phenylala-
nine 508, is responsible for the majority of CF cases world-
wide. The F508 allele represents ~70% of all CF-associ-
ated alleles; thus, given the recessive inheritance of the dis-
ease, 90% of CF patients carry at least one F508 allele.
The F508 mutation belongs to several classes. Because of
a severe folding defect resulting in degradation of most of
the protein translated at the endoplasmic reticulum (Class
II) (42, 148) coupled with thermal instability and an in-
creased rate of degradation once at the plasma membrane
(Class VI) (173, 251), the amount of mature, fully glycosy-
lated F508 CFTR protein in the plasma membrane is es-
timated to be only ~2% of that of wild type (WT) (239). In
addition, the small amount of F508 CFTR present in the
plasma membrane is phosphorylated by PKA at a dimin-
ished rate (246), and even fully phosphorylated F508
channels display a severe gating defect (Class III) character-
ized by a 40-fold reduction in channel open probability
because of a lower rate of pore opening (66, 125, 161).
A reduction of CFTR anion permeability is undoubtedly
one of the root causes of abnormal lung secretions that lead
to the ultimately lethal CF lung symptoms. However, CF
airway epithelia also show enhanced amiloride-sensitive
transepithelial potentials and short-circuit currents (28,
121, 122). Loss of an inhibitory effect of WT CFTR on the
amiloride-sensitive epithelial Na channel (ENaC), and
consequent ENaC overactivation, was thought to underlie
this observation, and increased Na absorption together
with the loss of Cl secretion was suggested to cause dehy-
dration of the airway surface liquid, impairing mucociliary
clearance and increasing susceptibility to infection (27). Al-
though initial electrophysiological studies of coexpressed
CFTR and ENaC in Xenopus oocytes did not detect any
inhibitory effect of CFTR on ENaC (165), studies in more
native systems do support this hypothesis. In primary nasal
epithelia, a Na-permeant channel had a higher open prob-
ability in cells obtained from CF patients than in those from
normal individuals (44). Biochemical studies demonstrated
that WT CFTR could protect ENaC from protease-depen-
dent activation in airway epithelial cells, but F508 CFTR
failed to do so (89, 128). This consistent picture was ques-
tioned, however, when CF pigs (both/ and homozygous
F508) were developed by the Welsh laboratory. These,
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like humans, developed lung disease and showed increased
susceptibility to bacterial infection when newborn. A re-
duced pH of the airway surface liquid was found to be
crucial in developing the disease (181) (see Section IIIC), but
increased Na absorption was not detected (39, 110), sug-
gesting that amiloride-sensitive changes in epithelial prop-
erties might be secondary to reduced apical Cl permeabil-
ity. However, using a biophysical model of transepithelial
ion fluxes, alterations in bioelectric properties of CF epithe-
lia were found to be too large to be accounted for by elec-
trical coupling alone (170). Thus, a more complex interpre-
tation of CF pathogenesis might be required before decades
of controversy can be finally laid to rest.
II. CFTR DOMAIN TOPOLOGY AND
STRUCTURE
A. Domain Boundaries
Cloning of the CFTR sequence revealed its domain organiza-
tion (FIGURE1A) and allowed a roughpredictionof transmem-
brane topology and domain boundaries (201). The suggested
topology has stood the test of time, except for some small
adjustments of helical boundaries [e.g., (86, 255)]. However,
the originally predicted NH2- and COOH-termini of NBD1
and 2 turned out to be quite inaccurate. ExploitingABC trans-
porter modular architecture, coexpression of complementary
CFTR segments was used to provide a functional definition of
NBD1 boundaries (33): this approach extended the NBD1
COOH-terminus from amino acid position (a.a.) 586 to 633,
but left its NH2-terminus uncorrected. The crystal structure of
mouse CFTR NBD1 (130) finally assigned correct NBD1
NH2- andCOOH-terminal boundaries to~a.a. 390and~670,
respectively, although residues distal from ~a.a. 645 form a
helix that is not conserved among ABC proteins and contains
two consensus serines (S660 and S670) phosphorylated by
PKA, suggesting that it might be considered part of the R
domain. ForNBD2, the crystal structure of a fusion protein of
human CFTR NBD2 with the regulatory domain of Esche-
richia coli MalK (PDBID: 3GD7) allowed adjustment of
NBD2 NH2- and COOH-terminal boundaries to a.a. 1208
and ~1427, respectively, largely confirmed (1207–1436) by
the first atomic structure of full-length human CFTR (145).
Given that much of the R domain of CFTR is unstructured
(145, 177), its exact NH2- and COOH-terminal boundaries
are still uncertain andmight be assigned to ~a.a. 645 (670) and
~845, respectively, largely based on the boundaries of its
bracketing domains (NBD1 and TMD2; see FIGURE 1A) as
well as on the locations of consensus sites for PKA phosphor-
ylation.
B. The ATP Binding Cassettes
NBD1 and NBD2 are also known as CFTR’s ATP binding
cassettes, the highly conserved (both at a sequence and
three-dimensional structure level) ATPase subunits charac-
teristic of all ABC proteins (FIGURE 1B). ABC NBD struc-
tures consist of two subdomains. The nucleotide binding
core subdomain (the “head”) comprises an F1-like parallel
-sheet (FIGURE 1B, light green), which is stabilized by -he-
lices (FIGURE 1B, dark green) and contains the conserved
Walker A (consensus GXXXXGKS/T; FIGURE 1B, red) and
B (consensus DE,  hydrophobic; FIGURE 1B, ma-
rine) motifs important for Mg-ATP binding (245) and is
completed by an ABC-specific, three-stranded antiparallel
-sheet (FIGURE 1B, cyan). The two -sheets surround a
central -helix preceded by the P-loop, which is formed by
residues of the Walker A motif (FIGURE 1B, dark green helix
and red loop). The NBD -helical subdomain (the “tail”; FIG-
URE 1B, orange) contains the highly conserved, ABC-specific
“signature sequence” (consensus LSGGQ; FIGURE 1B, ma-
genta). In nucleotide-bound, high-resolution NBD structures,
the P-loop is seen to coordinate the phosphate chain, with the
conserved Walker A lysine (K464 and K1250 in CFTR; FIG-
URE1B, red sticks) playing a dominant role by coordinating all
three phosphates of ATP. The antiparallel -sheet provides a
conserved aromatic residue that stacks against the adenine
base of the bound nucleotide (W401 and Y1219 in CFTR;
FIGURE 1B, blue sticks). The Walker B motif ends in a con-
served aspartate (D572 and D1370 in CFTR; FIGURE 1B,ma-
rine sticks) important for Mg2 coordination and is followed
by a conserved glutamate (E1371 in NBD2 of CFTR; FIGURE
1B, salmon sticks), which acts as the general base that polar-
izes the attacking water molecule during the ATP hydrolysis
reaction (162, 174, 175). A conserved glutamine (Q493 and
Q1291 in CFTR; FIGURE 1B; orange sticks) in the loop that
links the head and tail subdomains (the “Q-loop”) acts as the
-phosphate sensor and plays a key role in an induced fit
conformational change elicited by ATP binding; an ~15° rota-
tion of the tail subdomain toward the core subdomain in ATP
compared with ADP-bound, or apo, structures (115, 268).
These key catalytic residues are held together by the conserved
“switch histidine” (H1402 in NBD2 of CFTR; FIGURE 1B,
light magenta sticks), also called the “linchpin” (174, 269). In
CFTR, there is substantial asymmetry between NBD1 and
NBD2regarding the key consensusmotifs. InNBD1, the post–
Walker B glutamate and the switch histidine are replaced by
serines (S573 and S605, respectively), whereas in NBD2, the
signature sequence is atypical (LSHGH). In addition, CFTR’s
NBD1 contains two unique sequence segments (130): an ~30-
residue unstructured segment (a.a. 406–436) inserted into the
antiparallel -sheet [regulatory insertion (RI)], and an ~30-
residue helical extension [a.a. 641–670; regulatory extension
(RE)]. Both segments contain consensus serines phosphory-
lated by PKA (S422 and S660 and S670, respectively), and
both are unstructured in full-length CFTR (FIGURE 1B; light
magenta dotted lines).
In the presence of ATP, but under conditions that preclude
ATP hydrolysis, isolated ABC NBDs form head-to-tail
dimers that occlude two molecules of ATP at the dimer
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interfaces. SuchNBDdimerization can be observed both for
isolated soluble NBD domains [e.g., (38, 215, 269)] or in
the context of full-length ABC proteins [e.g., (46, 67, 256)],
including CFTR [(99, 159, 207, 274); FIGURE 1C]. In both
composite nucleotide binding sites, an ATP is sandwiched
between theWalker motifs of oneNBD (FIGURE 1C,Walker
A, red) and the signature sequence of the other NBD (FIG-
URE 1C, magenta). This arrangement explains the crucial
role the signature sequence plays in catalysis despite its
distance from the bound nucleotide within an NBD mono-
mer (FIGURE 1B). Furthermore, in CFTR, the head-to-tail
arrangement of the NBD dimer collects all noncanonical
substitutions into a single-composite binding site formed by
the head of NBD1 and the tail of NBD2 (site 1; FIGURE 1D,
upper site); in this degenerate site, the catalytic glutamate
and the switch histidine are ablated by mutation, and the
signature sequence is aberrant. In contrast, in the composite
binding site formed by the head of NBD2 and the tail of
NBD1 (site 2; FIGURE 1D, lower site), all key residues are
canonical. A similar asymmetrical distribution of consensus
versus atypical residues is found throughout the entire
ABCC subfamily as well as in many other prokaryotic and
eukaryotic heterodimeric ABC proteins (101, 187).
C. Structural Organization of Full-Length
CFTR
The overall three-dimensional arrangement of full-length
CFTR was resolved in a series of recent atomic resolution
structures obtained by cryo-electron microscopy (cryo-
EM), two from zebrafish CFTR (273, 274) and one from
the human protein (145). Although at present no functional
information is available on zebrafish CFTR, which is only
~55% identical in sequence to the human protein, the struc-
tures of the two orthologs in their dephosphorylated apo-
states are virtually identical (root mean square deviation
~1.9Å across the entire protein), suggesting that structural
information obtained from the zebrafish ortholog is largely
relevant to the human protein.
The global arrangement of the CFTR protein (FIGURE 1E–F)
resembles that of other ABC exporters (46, 67, 212, 256),
as had been predicted by extensive cross-linking studies (99,
159, 207). The membrane-spanning components are
formed by the twelve transmembrane helices, six from
TMD1 (FIGURE 1E–F, light gray) and six from TMD2 (FIG-
URE 1E–F, dark gray), which also extend deep into the cy-
tosol. TMD/NBD interactions occur via four short coupling
helices (CH1–4; FIGURE 1E–F,magenta) formed by intracel-
lular loops 1 (CH1; aa. 168–174) and 2 (CH2; aa. 269–
275) of TMD1 and the analogous intracellular loops 3
(CH3; aa. 961–966) and 4 (CH4; aa. 1062–1068) of
TMD2. As for other ABC exporters, TMD1 and TMD2 do
not form distinct, separate bundles of transmembrane heli-
ces but are closely intertwined with each other as well as
with the NBDs. In particular, a unit formed by TM4/CH2/
TM5 reaches out from TMD1 and contacts NBD2 and in a
similar fashion, TM10/CH4/TM11 extends from TMD2
toward NBD1 [domain swap (67)]. Thus, the full-length
CFTR molecule can be seen to be formed by two structural
halves [TMhelices 1, 2, 3, 6 plus 10, and 11withNBD1 and
TM helices 7, 8, 9, 12 plus 4, and 5 with NBD2 (274),
FIGURE 1E]. The coupling helices run roughly parallel with
the plane of the membrane and fit into corresponding clefts
on the NBD surfaces, forming ball-and-socket–like joints
that are the transmission interfaces for communications be-
tween the NBDs and the TMDs. Because of deletion of a
short helix from NBD1, the “socket” on the NBD1 surface
that accepts CH4 is shallower than the NBD2 socket that
accepts CH2 (compare sockets in FIGURE 1B), rendering the
NBD1/CH4 interfacemore sensitive to deleterious effects of
mutations. This explains the severe structural destabiliza-
tion caused by deletion (or mutations) of phenylalanine 508
(FIGURE 1B, NBD1, purple sticks), which contributes a hy-
drophobic side chain to formation of the shallow NBD1
socket (273).
Experimentally observed conformations of ABC proteins
fall into two major classes. First, in most structures solved
in the absence of nucleotide (apo-structures), the TMDs
adopt an inward-facing conformation in which the extra-
cellular ends of the TM helices are tightly bundled, whereas
their cytosolic extensions, including the coupling helices,
are spread apart, and the NBDs are separated (8, 101,
212, 256). Among the many solved inward-facing struc-
tures of ABC proteins, the observed degree of separation
between NBD interfaces is highly variable. In the struc-
ture of dephosphorylated apo-CFTR [both zebrafish
(273) and human (145)], the NBD interface separation is
relatively large (17Å; FIGURE 1E). Second, in nucle-
otide-bound ABC-exporter structures solved under con-
ditions that preclude ATP hydrolysis, the TMDs typically
adopt an outward-facing orientation in which the cyto-
solic ends of the TM helices are tightly bundled, the
coupling helices approach each other, and the NBDs are
tightly dimerized. In such structures, a variable degree of
separation is observed between the extracellular ends of
the TM helices, ranging from widely splayed extracellu-
lar loops (67, 256) to more compact bundling (46). The
structure of phosphorylated, ATP-bound zebrafish CFTR
is in an outward-facing conformation (274) resembling
the latter, tighter extracellular bundling arrangement,
with the TM helices largely parallel to each other [FIGURE
1F; see also (52)].
In addition to these mostly expected general ABC protein
characteristics, the recent CFTR structures revealed several
unpredicted features. The NH2-terminal ~60 residues, con-
served throughout the ABCC subfamily and unique to it,
form a “lasso motif” (FIGURE 1E–F, red). The lasso contains
two -helices, the first of which is partly inserted in the
membrane, packed against TMD2. The second, amphi-
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pathic helix, which runs parallel to the membrane and ex-
poses a highly charged surface to the aqueous environment,
has been implicated in both channel trafficking and gating
regulation (166, 167). Further unique features of CFTR’s
TMDs are likely essential for its ion channel function. The
pseudosymmetry of the TM helices is disrupted by a discon-
tinuity of TM helix 8 [TM8 (51)], which makes two sharp
breaks within the membrane (FIGURE 1F, right; TM8 exter-
nal segment and helical breaks are highlighted in cyan),
thereby displacing TM7 from its ABC-typical location (FIG-
URE 1F, right, pale green). As a consequence, the central ion
pore is mostly lined by TM1 and 6 of TMD1, and by TM8
and 12 of TMD2, consistent with earlier accessibility stud-
ies (12, 85, 88, 188, 254, 255, 271). In ABC transporters,
access to the substrate translocation pathway is gated at
both ends: the external gate is open in the outward-facing
TMD conformation, whereas the internal gate opens in the
inward-facing state. In contrast, in the CFTR channel, the
open pore provides a continuous aqueous transmembrane
pathway permeable to anions. Given that the open CFTR
pore corresponds to an outward-facing TMD conforma-
tion, an aqueous pathway must exist that bypasses the
closed internal ABC transporter gate. Consistent with re-
sults of functional (76, 77) and modeling (52, 163) studies,
in the corresponding CFTR structure (274), that pathway is
formed by a lateral opening (FIGURE 1F, red arrow) between
TM4 (FIGURE 1F, yellow) and 6 (FIGURE 1F, orange) that
connects the cytosolic environment with the internal vesti-
bule of the pore.
D. Structural Information on the R Domain
The entirely unique amino acid sequence of the R domain is
a consequence of its evolutionary origin from an intronic
DNA sequence (205). Although early circular dichroism
(CD) spectra of an R domain peptide, based on the origi-
nally suggested domain boundaries (a.a. 595–831), re-
ported some -helical content to a degree influenced by
phosphorylation and identified an NH2-terminal sub-
domain with high sequence conservation among CFTR or-
thologs (residues 587–672) (72), the latter segment, in fact,
largely belongs to NBD1. In contrast, CD spectra of an R
domain peptide encompassing a.a. 708–831 predicted this
domain to be largely unstructured (177), consistent with its
origin from noncoding sequence. Nevertheless, biochemical
pull-down assays and NMR studies with isolated peptides
suggested that the R domain interacts with other parts of
the channel in a phosphorylation-dependent manner (29,
36, 249). In the dephosphorylated closed apo-structures of
both zebrafish (273) and human (145) CFTR, a large amor-
phous density corresponding to the R domain is seen
wedged between the two CFTR halves, interacting with
NBD1 and the cytosolic ends of the TM helices; in the
dephosphorylated human structure, a part of the density
that interacts with the TM helices can be modeled as an
-helix (FIGURE 1E, yellow surface plot) and likely corre-
sponds to the COOH-terminal end of the R domain (a.a.
825–843). Such an intercalated arrangement of the dephos-
phorylated R domain is sterically incompatible with NBD
dimerization or with an outward-facing conformation of
the TMDs. Indeed, in the phosphorylated, ATP-bound, out-
ward-facing zebrafish CFTR structure (274) (FIGURE 1F),
no density corresponding to the R domain is observed, in-
dicating that this region does not adopt a common confor-
mation in most of the analyzed particles but, instead, be-
comes disordered.
III. THE CFTR ANION PERMEATION
PATHWAY
A. Structural Segments Lining the Pore
Long before the availability of high-resolution structural
information, several of CFTR’s helices had been probed for
their contributions to the ion permeation pathway by use of
the substituted cysteine accessibility method. Such studies
identified TMhelices 1 (85, 88, 254), 5 (271), 6 (11, 75, 88),
11 (78, 255), and 12 (17, 78, 188) as pore lining. The
accessibility patterns were generally consistent with helical
structures, with each third-to-fourth-substituted residue be-
ing accessible from the ion permeation pathway, and the
patterns even predicted some symmetry break by suggesting
that TM7 does not participate in forming the pore (255,
271). A lateral portal serving as the cytosolic entrance of the
pore vestibule between the cytosolic extensions of TM4 and
6 was hypothesized (52, 163) and later experimentally con-
firmed. It is lined by a number of positively charged amino
acid side chains that play a role in attracting cytoplasmic
chloride ions to the inner mouth of the pore [(76, 77); some
of the corresponding residues in zebrafish CFTR are high-
lighted as blue spheres in FIGURE 1F, right]. Except for the
unanticipated helical break observed in TM8 (FIGURE 1F,
right, cyan), the recent cryo-EM structures largely con-
firmed the predictions of these functional studies and re-
vealed that the entire inner surface of the pore is lined by
positively charged residues, as expected for an anion chan-
nel (273).
B. Location of the Channel Gate
A deep and wide intracellular (12, 141, 211, 221, 279), and
a shallower extracellular (169, 218), vestibule predicted
from the voltage dependence of pore block by various large
organic anions suggested an asymmetric hourglass shape
for the CFTR pore. This shape positioned the gate, corre-
sponding to a narrow constriction in the permeation path-
way [with a functional diameter of ~5.3A (106, 144) in the
open conformation], close to the extracellular membrane
surface, at the level of TM6 residues 338–341 (63, 75, 87).
Consistent with a gate located at the extracellular end of the
pore, binding of large organic anion pore blockers (59) or
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ATP (219) in the intracellular vestibule does not prevent
gate closure. In the inward-facing structures of zebrafish
(273) and human [(145); FIGURE 1E], CFTR, the funnel-
shaped intracellular vestibule, indeed tapers down to a nar-
row tunnel at the predicted location of the gate, consistent
with those structures representing closed CFTR channels.
Interestingly, however, in the outward-facing structure of
phosphorylated ATP-bound zebrafish CFTR (274), al-
though this gate constriction between TM6, TM1, and
TM11 widens as expected, access to the pore from the ex-
tracellular space is nevertheless prevented by the extracel-
lular segments of TM helices 8 and 12 (FIGURE 1F, right,
cyan and dark cyan); this results from a local reorientation
of these two secondary structure elements with respect to
the rest of the half molecule. A structure of the CFTR pore
in its fully conductive conformation remains to be captured.
C. Mechanism of Anion Selectivity
The CFTR pore shows high anion versus cation selectivity
[the relative permeability of Na compared with Cl(pNa/
pCl) is ~0.03 (226)] but poorly selects among anions. Ex-
perimentally obtained anion permeability sequences (which
report relative ease of ion entry into the pore) are consistent
with a lyotropic selection mechanism; relative permeability
of a given anion is inversely proportional to its energy of
dehydration (140, 157, 216). For instance, compared with
chloride, large anions like SCN and nitrate, which more
easily shed their hydration shell, display higher permeabil-
ity through CFTR [e.g., pSCN/pCl 2.4 (140, 157)]. On the
other hand, these high-permeability, large anions also typ-
ically bind very tightly within the pore, resulting in a low
throughput rate operationally defined bymeasuring relative
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conductance [e.g., the relative conductance for SCN com-
pared with Cl(gSCN/gCl) is 0.2 (135, 157)]. Thus, evolu-
tion seems to have optimized the CFTR pore to provide
maximal conductance for the physiologically most relevant
anion, chloride (135). Besides chloride, the other physiolog-
ically relevant ion that permeates through CFTR is bicar-
bonate. CFTR’s relative permeability (pHCO3/pCl) and rela-
tive conductance (gHCO3/gCl) for bicarbonate are both
~0.25 (144, 184). Low permeability ratios were initially
also found in isolated pancreatic ducts (91), and CFTR’s
role in bicarbonate secretion was thought to be indirect,
mediated by regulation of Cl/HCO3
 exchangers of the
SLC26A family [reviewed in (129)]. However, several stud-
ies have raised the possibility that direct HCO3
 perme-
ation through CFTRmight become important, especially in
some physiological conditions (108), and that CFTR anion
permeability might be dynamically regulated (178, 198). Re-
gardless of the exact mechanism, CFTR-dependent bicarbon-
ate secretion clearly plays an important physiological role in
controlling the pHof the fluid layers that line various epithelial
surfaces (189, 202), including the lung (181, 210), as demon-
strated by the correlations seen between levels of CFTR, bicar-
bonate fluxes, and strength of lung host defense defects (208).
The region responsible for CFTR’s lyotropic selectivity (i.e.,
the region that provides sites of interaction for permeating
anions) corresponds to the narrow region of the pore, as
evidenced by changes in anion selectivity sequences upon
mutation of residues F337, T338, S341, S1118, or T1134
(90, 135, 140, 157, 158, 275). In addition, the large number
of positively charged residues that line the entire internal
surface of the pore [in particular, residue K95 in the internal
vestibule (137, 139)] or flank the cytoplasmic lateral open-
ing [(76, 77); cf., FIGURE 1F, right, blue spheres] contribute
to enhancing chloride conductance by attracting chloride
ions to the pore (139). Thus, it has been suggested that the
anion selectivity characteristics of CFTR might result from
at least two distinct selectivity filters operating in series,
interactions between permeant anions and the pore con-
striction around F337 being largely responsible for deter-
mining the selectivity of permeability, whereas anion/pore
interactions in the inner vestibule and around the entrance
of the lateral portal determine anion over cation selectivity
and boost anion conductance (139). Some evidence sug-
gests that overall high conductance and tight pore binding
of CFTR might result from simultaneous, multiple interac-
tions of permeating anions along the permeation pathway
(138). Channel pores with multiple ion binding sites often
show a nonlinear dependence of unitary conductance on the
mole fractions of two types of permeant ion that are simul-
taneously present. In the case of CFTR, such anomalous
mole fraction behavior has been reported for the anion pairs
Cl/SCN (136, 139) and Cl/SO4
2 (60).
By stabilizing the open-pore structure, anion/pore interac-
tions contribute to the energetic stability, and therefore the
life time, of the open-channel state. Thus, anion replace-
ment affects not only permeation properties, but also the
kinetics of gating transitions: nitrate and bromide, which
bind more tightly than chloride delay, whereas formate,
which binds less tightly than chloride, accelerates pore clo-
sure (219, 266). These effects of tight-binding permeating
ions to retard the closing of the CFTR gate might be anal-
ogous to the influence exerted by a substrate bound to an
outward-facing exporter; extracellular release of the sub-
strate favors closing of the extracellular gate, and thus res-
toration of the inward-facing conformation [see Section
IVG; see also (266)].
D. Pore Blockers
Many large organic anions block the CFTR pore when ap-
plied from the intracellular side. The resulting brief closed
events (flickery block) reflect the brief residence time of the
blocker at its binding site in the pore. Pore block is more
pronounced at hyperpolarized (more negative) membrane
potentials that drive the negatively charged blocker into the
FIGURE 1. CFTR domain topology and structure. A: CFTR domain topology. TMD1 (light gray), TMD2 (dark gray), intracellular loops (light
purple), NBD1 (blue), NBD2 (green), regulatory (R) domain (rose), and membrane (yellow). B: Ribbon representation of NBD1 (left) and NBD2
(right) from the cryo-electron microscopy (cryo-EM) structure of the phosphorylated, ATP-bound form of zebrafish CFTR (PDBID: 5W81). F1-like
parallel -sheet plus -helices (green), ABC-specific antiparallel -sheet (cyan), -helical subdomain (orange), Walker A motif (red), Walker B
motif (marine), signature motif (magenta), ATP (yellow sticks), and Mg2 ion (slate sphere). The numbering of the conserved residues shown in
stick representation is based on the human CFTR sequence. An E–Q mutation of the catalytic glutamate in NBD2 was used to trap the protein
in an ATP-bound form. In NBD1, light magenta dotted lines mark the locations in the primary sequence of the unresolved regulatory insertion
(RI) and regulatory extension (RE). C: Organization of the ATP-bound, head-to-tail NBD1/NBD2 heterodimer (from PDBID: 5W81). NBD1 (blue),
NBD2 (green), ATP molecules (yellow sticks), Walker A motifs (red), and signature sequences (magenta). The conserved Walker A lysines are
shown as red spheres. D: Cartoon representation of residue asymmery in the CFTR NBD dimer; color coding of conserved residues as in B. The
upper site (site 1, degenerate site) harbours all noncanonical substitutions, whereas in the lower site (site 2, canonical site), all catalytically
important side chains are intact. E: Ribbon representation of the dephosphorylated human CFTR apo-structure (PDBID: 5UAK); domain color
coding as in A. Lasso motif (red), R domain helix modeled into observed density (yellow surface), coupling helices (magenta), ATP (yellow sticks),
and membrane (horizontal gray lines). F: Ribbon representations of the structure of phosphorylated, ATP-bound CFTR (PDBID: 5W81) viewed
from two different orientations; left view and domain color coding as in E. The view to the right shows the cytoplasmic opening of the ion
permeation pathway (red arrow, lateral opening) flanked by transmembrane (TM) helices 4 (yellow) and 6 (orange); positively charged residues
lining the opening are shown as blue spheres. Outer segments of TM8 and TM12 are colored (cyan and deep cyan); TM7 is pale green; the lasso
motif has been removed for clarity.
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intracellular pore vestibule but is alleviated at depolarized
(more positive) membrane potentials. The steepness of this
voltage dependence allows estimation of how deep the
blocker binding site is [i.e., what fraction of the membrane
electrical field the blocker traverses before reaching its bind-
ing site ()]. Similar voltage dependences suggest a common
binding site for a structurally diverse group of blockers
including diphenylamine-2-carboxylate, flufenamic acid
[ ~0.41 for both (156)], glibenclamide [ ~0.45–0.48
(211, 279)], 5-nitro-2-(3-phenylpropylamino)benzoate
(NPPB) [ ~0.5 (59)], 3-(N-morpholino)propanesulfonic
acid (MOPS) [  ~0.5 (59, 109)], and anthracene-9-
carboxylic acid [  ~0.5 (1)]. In line with the notion of a
common binding site, glibenclamide and isethionate (279),
or NPPB and MOPS (60), were shown to compete for pore
block. Mutagenesis studies highlighted how the positively
charged side chain of the pore-lining residue K95 plays an
important role in interacting not only with permeant an-
ions, but also with blockers (137). In the atomic structure of
human CFTR, K95 is located at a position where the intra-
cellular vestibule tapers down to the narrow tunnel believed
to comprise the gate (145). Of note, an intrahelical salt
bridge between the side chains of K95 and E92 was recently
noted in the cryo-EM structure of human CFTR and pro-
posed to play a role in anion/pore and blocker/pore inter-
actions (104). Consistent with the binding site for diverse
blockers being located intracellular to the channel gate, the
presence of NPPB or MOPS in the pore does not delay gate
closure (59). More modest voltage dependences reported
for block by the disulfonic stilbenes 4,4= diisothiocyanostil-
bene-2,2=-disulfonic acid and 4,4=-dinitrostilbene-2,2=-
disulfonic acid [  ~0.16 and   ~0.34, respectively
(141)] suggest that a more superficial blocker binding site
might also exist.
Whereas the above compounds block from the cytosolic
side and show low affinity for the CFTR pore (Kd in the
hundreds of micromolar to millimolar range at 0 mV mem-
brane potential), high-throughput screening has led to the
discovery of a higher-affinity pore blocker that acts from the
extracellular side; N-(2-naphthalenyl)-[(3,5-dibromo-2,4-
dihydroxyphenyl)methylene]glycine hydrazide (GlyH-101)
blocks CFTR currents with a Kd of ~4 M at 0 mV mem-
brane potential and shows the inverse voltage dependence
expected for an anionic blocker that binds in the extracel-
lular vestibule (164). The electrical distance of the GlyH-
101 binding site (  0.35) and strong reductions in appar-
ent affinity by mutation R334C (62) or upon covalent mod-
ification of a cysteine engineered into position 338 (169)
suggest that GlyH-101 binds at the bottom of the shallow
extracellular vestibule, just above the constriction that
forms the channel gate (169).
E. Intraburst (Flickery) Closures
Under all experimental conditions, gating of single CFTR
channels shows clear bursting behavior; groups of open
events interrupted by brief (~1–3 ms at 37°C and ~10 ms
at 25°C) flickery closed events form bursts that are sep-
arated from each other by long (~0.1–0.2 s at 37°C and
~0.4–2 s at 25°C) interburst closed events. Some of the
brief intraburst closures represent block by large cytoso-
lic anions (278) or by anionic buffer molecules present in
the recording solution that bathes the cytosolic mem-
brane surface (109); indeed, even cytosolic ATP causes
low-affinity pore block (219). But not all intraburst clo-
sures may be accounted for by such a mechanism, be-
cause flickery closures can be observed for locked/open
channels long after ATP has been washed away, even in a
cytosolic solution buffered with a cationic buffer (279),
and also when channel currents are studied at positive
voltages (243), which deter cytosolic anion entry. Thus,
at least a fraction of the observed flickery closures must
represent a gating mechanism intrinsic to the channel
protein.
Several studies have addressed the dependence of in-
traburst gating kinetics on a variety of factors, including
voltage, pH, or the concentration of ATP used for chan-
nel activation. Both the frequency and the duration of
flickery closures increases at positive membrane poten-
tials, reporting a weak voltage dependence of intraburst
gating (30). Acidification of the bath solution to
pH  6.3 prolongs the average duration of flickers by
approximately twofold (40). In contrast, neither the fre-
quency nor the duration of intraburst closures is sensitive
to the concentration of applied ATP (243, 261). Finally,
mean flickery closed time is prolonged by catalytic site
mutations that disrupt ATP hydrolysis (243) because of
the appearance of a second population of intraburst
closed events with an average life time of ~50–100 ms
(25, 61). As a result, intraburst closures lasting up to
several hundred milliseconds may be observed during
long locked/open bursts and have been dubbed “gating”
in some reports (172). Although temperature dependence
of intraburst kinetics has not yet been addressed system-
atically, comparison of studies conducted at room tem-
perature (20–25°C) and those obtained at 37°C suggests
approximately three- to fivefold briefer flickers at the
higher temperature [e.g., (243) versus (30)].
Two alternative kinetic mechanisms, Cslow↔Cfast↔Oand
Cslow↔ O↔ Cfast, with Cslow and Cfast denoting the inter-
burst and intraburst closed states, respectively, have been
used to model CFTR bursting behavior. Because these two
schemes cannot be distinguished by steady-state recordings,
all data available to date may be explained equally well by
either scheme. In such situations, it is customary to prefer
the scheme which requires adjustment of the smaller num-
ber of parameters to describe two data sets obtained under
two different experimental conditions. However, even that
“parsimony argument” has been of no help so far as for
either model, only one rate was found to be sensitive to ATP
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concentration (243, 261), but several to both voltage (30)
and intracellular pH (40).
The physical mechanism underlying flickery closures is still
elusive. The slow and fast gates that cause inter- and in-
traburst closures, respectively, may or may not be formed
by two physically distinct protein regions. But slow and fast
gating certainly reflect two distinct types of TMD confor-
mational change; slow gating (i.e., entering and exiting a
burst) likely represents flipping between TMD conforma-
tions that are analogous to inward- and outward-facing
conformations of ABC exporters, respectively (146, 242),
whereas fast gating (i.e., intraburst flickering) is likely
caused by a smaller-scale, more localized conformational
change. One possibility is that the outward-facing occluded
structure seen for phosphorylated zebrafish CFTR (274), in
which the pathway is blocked by a local distortion of the
outer segments of TM helices 8 and 12, represents the flick-
ery closed state. As described above, in that conformation,
the gate constriction is widened, but the external extremity
of the ion conduction pathway is blocked by a localized
conformational change of the outer-leaflet segments of TM
helices 8 and 12 (FIGURE 1F, right, cyan and dark cyan).
However, given that the (human) CFTR channel dwells in
the flickery closed state only for a small fraction of the
total duration of a burst, capturing this conformation in
a cryo-EM structure is unlikely, unless it is stabilized by
some factor specific to the cryo-EM conditions (e.g., spe-
cies difference or low temperature). Thus, an alternative
interpretation of the outward-facing occluded zebrafish
CFTR structure is that it represents an intraburst closed
state with a high occupancy probability but a lifetime too
short (~1 s) to be resolved in limited-bandwidth elec-
trophysiological recordings; in that case, the experimen-
tally measured unitary conductance of 7–10 pS would
reflect the full conductance multiplied by the fraction of
time the pore is truly open within a burst (274). Molec-
ular dynamics simulations, encompassing 1.5 s, high-
light the relative stability of the outward-occluded con-
formation seen in the ATP-bound zebrafish structure
(51), disfavoring the latter scenario. Thus it remains pos-
sible that for both interburst and conventional flickery
closures, the ion conduction pathway is interrupted by a
similar conformation of the narrow constriction between
TM helices 1, 6, 8, and 12 observed at the height of TM6
residues 338–341 [the gate (273)].
IV. REGULATION OF CFTR GATING
THROUGH NUCLEOTIDE INTERACTIONS
AT THE NBDs
Because phosphorylation and ATP regulate slow gating, in
the following sections, channel “opening” and “closing”
will be used synonymously with entering and exiting a
burst.
A. ATP Hydrolysis at One of Two
Nonequivalent Composite ATP Binding
Sites
The catalytic turnover rate of CFTR ATPase activity (0.5–1
s1), estimated for phosphorylated human CFTR protein
purified to homogeneity (131, 145), falls into the range of
channel gating (bursting) rates. An early hint that ATPase
activity might be coupled to pore gating was provided by
the observation that lowering freeMg2 to 4 nM, or adding
Na-azide, inhibited both processes (131). The catalytic ac-
tivity of the CFTR protein must originate from composite
site 2 of the NBDs, because mutation of theWalker A lysine
in site 2, but not that in site 1, abolishes ATPase activity
(192). Indeed, photocrosslinking experiments revealed that
site 1 retains ATP bound and unhydrolyzed for up to tens of
minutes (7, 14). The presence of canonical consensus motifs
in site 2, but noncanonical residues in site 1 (FIGURE 1D),
readily explains such functional asymmetry between
CFTR’s two composite ATP binding sites and is likely a
shared feature of asymmetric ABC proteins (102, 186, 235)
[including the entire human ABCC subfamily as well as
many heterodimeric prokaryotic homologs (187)].
B. Coupling of Pore Opening/Closure to
Formation/Disruption of a Head-to-Tail
NBD Heterodimer
Decades of experimental work gathering information on
both CFTR and related ABC proteins have clarified the
basic mechanism by which ATP binding and hydrolysis at
the NBDs drives pore gating in CFTR. Early studies dem-
onstrated that preventing (or attenuating) ATP hydrolysis
in site 2 by mutations of the Walker A lysine (K1250A/G/
M/T) or the catalytic glutamate (E1371Q/S) in NBD2 (FIG-
URE 1B, right; FIGURE 1D) locks channels in the open burst-
ing state (32, 96, 242, 243) for time intervals at least two
orders of magnitude longer than the mean burst duration of
WT CFTR. These results clearly demonstrated that site 2
ATP hydrolysis is required for normal (fast) termination of
a burst. Mixtures of ATP either with nonhydrolyzable ATP
analogs, such as 5=-adenylyl-imidodiphosphate (AMPPNP)
or adenosine 5=-(gamma-thiotriphosphate) (ATPS), or
with pyrophosphate (PPi) also lock channels open (95,
103), suggesting that these analogs prevent closure by bind-
ing at site 2. A similar lock-open effect of mixtures of ATP
with the inorganic phosphate (Pi) analog orthovanadate
(Vi) is believed to reflect formation of a stable ADP:Vi com-
plex that resembles the pentacovalent transition state of the
ATP hydrolysis reaction in site 2 (15, 95). Formation of
such complexes by the hydrolysis product ADP and a Pi
analog that binds tightly in place of the released Pi has been
observed in atomic structures of ABC proteins (174).
Contrary to early conclusions obtained mostly on single
CFTR channels (9, 103, 203), nonhydrolyzable ATP ana-
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logs, such as AMPPNP, ATPS, ,-methyleneadenosine
5=-triphosphate (AMPPCP) (4, 243), or PPi (234), alone are
capable of opening CFTR channels, although the nucleotide
analogs are poor substitutes for ATP, supporting amaximal
opening rate only ~5% of that observed in saturating ATP
(243). Although the hydrolysis-abolishing K1250A muta-
tion was found to reduce not only closing, but also channel
opening rate (32, 192), the latter effect was later shown to
be largely due to a reduced ATP binding affinity in site 2
(243). Indeed, another site 2 mutation expected to disrupt
hydrolysis, E1371S, does not impair channel opening (243).
Thus, pore opening requires nucleotide binding, but, in con-
trast to channel closure, not hydrolysis.
By what mechanism is ATP binding at the NBDs translated
into pore opening? The hyperbolic dependence of channel
opening rate (i.e., the rate of entering a burst) on ATP
concentration [K1/2  ~50 M (55, 241, 243, 270)] indi-
cates a rate-limiting step for pore opening other than ATP
binding. That step is Mg2 dependent (71, 131) and must
follow ATP binding because its rate is sensitive to nucleo-
tide structure; maximal opening rates supported by
8-azido-ATP (14) or AMPPNP (243) are much lower than
that observed in ATP. Furthermore, ATP bindingmust have
happened at least at the NBD2 head before the pore opens,
because mutations of the Walker A lysine (K1250A, red),
the Walker B aspartate (D1370N, marine), or the stacking
aromatic residue (Y1219G, blue) in NBD2 (FIGURE 1B,
right), all of which destabilize ATP binding there, dramati-
cally reduce the apparent affinity for ATP to open the pore
(243, 281). In contrast, prior ATP binding to the NBD1
head (FIGURE 1B, left) seems less essential for channel open-
ing as the apparent potency of ATP in opening the pore is
decreased by some mutations that impair ATP binding
[K464A, removal of the Walker A lysine side chain, red
(243)], but not by others [W401G, removal of the stacking
aromatic side chain (281)]. The observation of tight NBD
dimers in ABC proteins in the presence of ATP and the
suggestion that NBD dimer formation/dissociation might
underlie the coupling of ATPase cycles to vectorial trans-
port of substrates by ABC transporters (162) prompted the
proposal that CFTR and transporters might share a com-
mon mechanism. Thus, in CFTR, the rate-limiting step for
pore opening (to a burst) would reflect formation of a tight
head-to-tail NBD1/NBD2 heterodimer, whereas closure
(from a burst) would occur upon disruption of that het-
erodimer [FIGURE 2E (243)].
A first formal proof of that hypothesis was provided by the
demonstration that two residues on opposing surfaces of
composite site 2 (arginine 555 just downstream of the
NBD1 signature sequence and threonine 1246 in the NBD2
Walker A motif) become energetically coupled upon chan-
nel opening, but not upon binding of ATP (which occurs on
closed channels, see above) (242). For steric reasons, a hy-
drogen bond observed between the side chains of the cor-
responding residues in dimeric ABC NBD structures (38,
215) is expected to form either between an arginine/threo-
nine (R/T) pair, as found in the sequence of CFTR and a
subset of ABC proteins, or between a lysine/asparagine
(K/N) pair, as present in a smaller subset of the ABC super-
family (FIGURE 2A), but not between R/N or K/T pairs
(which are poorly represented in naturally occurring ABC
sequences). A large reduction in channel opening rate (i.e.,
an increase in interburst duration, ib) observed when intro-
ducing the R555K or T1246N mutations in the WT CFTR
background (FIGURE 2C, blue and red bars versus black bar)
was not seen when introducing the same mutations into a
background already mutated at the other position (FIGURE
2C, purple bar versus blue or red bar). This suggests that
formation of the R555/T1246 hydrogen bond inWTCFTR
facilitates channel opening and that the hydrogen bond is
disrupted in each single mutant but restored in the double
mutant. These mutation-induced changes in opening rate
report mutational effects on the stability of the transition
state for opening (T‡) relative to the closed state (G‡T-C;
numbers next to arrows in FIGURE 2D). The R555K muta-
tion destabilizes the transition state when a threonine is
present at position 1246 (FIGURE 2D, left vertical arrow) but
stabilizes it when the residue at position 1246 is an aspara-
gine (FIGURE 2D, right vertical arrow). The difference be-
tween G‡T-C values along two parallel sides of the mu-
tant cycle quantifies the change in interaction energy be-
tween the native side chains upon entering the transition
state from the closed state [Gint(opening)], and is of a mag-
nitude and sign consistent with formation of a hydrogen
bond. A similar mutant cycle built on the closed/open equi-
librium constant of a hydrolysis deficient mutant, in which
gating is reduced to reversible C1↔O1 transitions, con-
firmed the presence of the R555/T1246 hydrogen bond also
in the open ground state (242). Chemical cross-linking ex-
periments (159) later confirmed the canonical head-to-tail
NBD dimer arrangement seen in all dimeric ABC NBD
structures (FIGURE 1C–D) to be present in full-length, gating
CFTR channels in their native environment.
Thus, the rate-limiting step for channel opening (FIGURE 2E,
step C1¡O1) consists of tight dimerization of ATP-bound
NBDs coupled to TMD rearrangements that open up a
transmembrane pathway for anions. Demonstration of salt
bridge formation between cytosolic TMD loops in the open
state (252), but between extracellular TMD loops in the
closed state (64, 107), as well as a proposed narrowing of
the intracellular vestibule in open channels (12) all sug-
gested that upon pore opening, CFTR’s TMDs undergo a
conformational change similar to the flipping of ABC trans-
porter TMDs from an inward- to an outward-facing con-
formation. All these predictions, based on functional stud-
ies, were largely confirmed by the recent cryo-EM structures
of dephosphorylated apo- and phosphorylated ATP-bound
CFTR [FIGURE 1E–F (145, 273, 274)].
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C. Thermodynamics and Timing of the Pore-
Opening Transition
Among the steps that a phosphorylated WT CFTR channel
follows around its gating cycle (FIGURE 2E), the pore-open-
ing transition (FIGURE 2E, step C1¡O1) is the slowest
(~0.5–2 s1 at 25°C and ~5–8 s1 at 37°C), reflecting a high
energetic barrier characterized by an unstable, high-free-
energy transition state. The most common CF mutation,
deletion of phenylalanine 508, further slows this step by
40-fold (125, 161). What is the nature of this transition
state, and what causes its high free energy? The steep tem-
perature dependence of WT CFTR opening rate signifies a
large activation enthalpy [H‡T-C  ~100–150 kJ/mol (6,
57, 155)], suggesting molecular strain. On the other hand,
the discrepancy between G‡T-C and H
‡
T-C signals a large
entropy increase in the transition state [TS‡T-C  40 kJ/
mol (57)]. Given that the NBD interface is already tightened
around ATP site 2 in the transition state [FIGURE 2A–D
(242)], the large activation entropy has been interpreted
to reflect the dispersal of the layers of ordered water
molecules that cover the interfacial NBD surfaces when
the NBDs are separated and the interface is open and
accessible to solvent (57).
The relative timing of motions in different regions of a
channel protein during the submicrosecond process of pore
opening (transition from state C toO) can be determined by
studying the kinetic consequences of structural perturba-
tions, typically point mutations, introduced into various
protein regions. If the perturbation-induced change in the
transition-state free energy linearly interpolates the differ-
ence,		Go, between the free energy changes of the C andO
ground states (		Go 
 	GO
o  	GC
o ) (94, 153), then the
free energy of the transition state for opening, T‡, will
change by 		Go (0    1). A larger  value indicates
FIGURE 2. Coupling of CFTR pore opening to NBD dimerization. A: An arginine/threonine (serine) or a
lysine/asparagine side chain pair is optimally positioned to form a salt bridge between CFTR positions 555 and
1246. B and C: Single-channel outward current traces (B: Vm  40 mV) and mean closed (interburst)
durations (C) of preposphorylated WT, R555K, T1246N, and R555K/T1246N CFTR channels gating in 5
mM Mg-ATP. D: Thermodynamic mutant cycle illustrating mutation-induced changes in G‡T-C (numbers next
to arrows); Gint(opening) is the difference between G
‡
T-C values along two parallel sides of the cycle. The four
corners of the cycle are represented by the pairs of residues present at positions 555 and 1246, respectively.
E: Cartoon gating cycle of phosphorylated CFTR. Color coding as in FIGURE 1A; the R domain is not depicted.
Site 1 (degenerate site), upper site; site 2 (canonical site), lower site; ATP, yellow circles; ADP, orange
crescent; chloride ions, dark red dots. [A–D adapted with permission from Vergani et al. (242)].
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earlier, and a smaller  value later, movement of the target
position during pore opening. In particular,   ~1 indi-
cates that, in the transition state, the target position is al-
ready near its open-state conformation, whereas   ~0
suggests it has not yet moved much from its closed confor-
mation (10, 277). Because the perturbation will change the
logarithm of the opening rate constant (kCO) by 		G
o⁄
RT, but the logarithm of the equilibrium constant (Keq)
by 		Go⁄RT,  can be estimated from the slope of a
rate-equilibrium free energy relationship (REFER) plot of
logkCO versus logKeq for a series of mutations at the target
position. Importantly, because the REFER approach as-
sumes equilibrium gating, with opening and closure reflect-
ing reversible transitions along a single kinetic pathway
(53), this approach cannot be applied to address the dynam-
ics of the ATP-dependent slow-gating process of WT CFTR
channels (5, 204), which obey a nonequilibrium cyclic gat-
ing mechanism (FIGURE 2E). However, the technique may
be adapted to studying the pore-opening step (FIGURE 2E,
step C1¡O1) by employing a background mutation that
disrupts ATP hydrolysis in site 2, thereby reducing gating to
reversible C1↔O1 transitions. REFER analysis in such a
nonhydrolytic background (NBD2Walker B aspartate mu-
tant D1370N) revealed a clear spatial -value gradient
along the protein’s longitudinal axis from cytoplasm to cell
exterior (219, 220);  was close to ~1 for both faces of
composite ATP site 2 (positions 555 and 1246; FIGURE 3A,
left, red spacefill; FIGURE 3A, right, red numbers) and ~0.5–
0.6 for positions in each of the four coupling helices (posi-
tions 172, 275, 961, and 1068, respectively; FIGURE 3A,
purple spacefill and numbers), but ~0.2 for the centrally
located pore residueM348 in TM6 and ~0 for position 117
in the first extracellular loop (FIGURE 3A, blue spacefill and
numbers). This clear -value gradient suggests that a
spreading conformational wave is initiated at the site 2
NBD interface and propagates toward the pore (FIGURE 3B,
vertical colored arrow). In particular, it suggests that in the
transition state the site 2 interface is already tightly
dimerized, but the pore is still closed (FIGURE 3B, center).
Thus, the high enthalpy of the opening transition state
(H‡T-C  ~100–150 kJ/mol) might reflect strain at the
NBD/TMD interface [(219); cf., (57)], which includes the
disease hotspot position 508. Indeed, a  value of ~0.5 for
position 508 suggests that this NBD position moves syn-
chronously with nearby TMD-coupling helix 4 (220). Inter-
estingly, a low-intermediate  value of ~0.4 was found for
both faces of degenerate site 1 (positions 460 and 1348;
FIGURE 3A, orange spacefill and numbers), reporting de-
layed movement here with respect to site 2 and suggesting
that site 1 residues are still on the move in the transition
state for channel opening. However, because such pro-
nounced asymmetry cannot be detected at the level of the
four coupling helices, it seems likely that the movements
completed in site 1 between the transition state and the
open state are localized movements confined to the site 1
NBD interface (220).
D. Strictness of Coupling Between Pore-
Opening Events and NBD Dimerization
Strict coupling between NBD dimerization and pore open-
ing in CFTR has been called into question because a con-
struct lacking NBD2 (NBD2, truncated after residue
1197) displays low-probability, ATP-independent openings
following phosphorylation by PKA (65, 248). Based on that
observation, spontaneous openings in the absence of ATP,
also seen occasionally in WT CFTR (25, 224) but robustly
promoted bymutations at TMDpositions 978 [ICL3 (253)]
or 355 [TM6 (257)], were interpreted as reflecting pore
openings in the absence of NBDdimerization. Furthermore,
a resemblance was noted between CFTR and classical li-
gand-gated channels, such as the nicotinic acetylcholine re-
ceptor, in that phosphorylation (248), TMD mutations
(253, 257), various drugs (112, 248), and ATP analogs
(172) all had strongly correlated effects on spontaneous
(ATP-independent) and on ATP-dependent channel activ-
ity, and the effects of such allosteric modulators were ener-
getically additive (172, 257). These analogies led to CFTR
FIGURE 3. Cytosolic to extracellular -value gradient and asym-
metry between sites 1 and 2. A: Cartoon representation of homol-
ogy models (52) of phosphorylated closed- (left) and open-state
(right) CFTR, with color coding as in FIGURE 1A; the regulatory (R)
domain is omitted. Target positions for rate-equilibrium free energy
relationship (REFER) analysis are highlighted in colored spacefill
(left), corresponding colored numbers illustrate estimated  values
(right). B: Cartoon representation of approximate structural rear-
rangements during the pore opening transition as the channel tran-
sits from an ATP-bound closed state (C1) through the transition
state (T) to the ATP-bound open state (O1). Site 1 (degenerate site),
upper site; site 2 (canonical site), lower site; color coding as in
FIGURE 2E. Vertical colored arrow illustrates the direction of the
spreading conformational wave. Red arcs in states T and O1 repre-
sent tight bonding across the NBD interface. [Adapted with permis-
sion from Sorum et al. (219) and Sorum et al. (220)].
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gating being modeled as an equilibrium loop mechanism in
which the ligand (ATP) can bind and unbind in both the
closed-pore and the open-pore conformation, and closed/
open (isomerization) transitions can occur whether or not
ligand is bound. In that model, because of the thermody-
namic principle of detailed balance, which constrains the
product of the equilibrium constants around a kinetic cycle
to be unity, higher affinity binding of the ligand in the
open-channel conformation would shift the closed/open
equilibrium of liganded channels toward the open state
[(120); cf., (92)]. An essential feature of such an allosteric
loop model [also key to the proposed reentry mechanism
(113) discussed in Section IVE, below] is the postulate that
in the ATP-free, spontaneous open state, the NBDs are dis-
engaged, and the dimer interface is therefore accessible for
ATP binding. Studying the accessibility of site 2 in ATP-free
open channels is not straightforward, but this question was
recently addressed by exploiting the enhanced spontaneous
activity of the K978C/P355A double mutant, which allows
quantitation of spontaneous gating parameters in micro-
scopic patches (160). In K978C/P355A channels gating in
the absence of ATP, just as in WT channels gating in the
presence of ATP (242) (Section IVB), energetic coupling
between site 2 residues R555 (NBD1 face) and T1246
(NBD2 face) was found to change in a state-dependent
manner; spontaneous open probability of the background
construct is reduced by both the R555K and the T1246N
single mutation, but restored in the double mutant (FIGURE
4A–B), reporting energetic coupling between these residues
in the open state (FIGURE 4C). Thus, the two side chains on
opposing faces of composite site 2 form a hydrogen bond in
the open-pore conformation, but not in the closed-pore
conformation, indicating the presence of a tightly dimerized
site 2 NBD interface in the spontaneous open-channel state
(FIGURE 4D), just as during normal, ATP-dependent open-
ings (FIGURE 2E). Because a tightly dimerizedNBD interface
does not allow ATP binding/unbinding in the open-pore
conformation, CFTR gating must be driven by principles
fundamentally different from the allosteric mechanisms
that underlie gating of ligand-gated channels. Thus, strict
FIGURE 4. Spontaneous pore openings are also coupled to NBD dimerization. A: Microscopic inside-out
patch recordings of CFTR background construct P355A/K978C and of channels bearing mutations R555K,
T1246N, and R555K/T1246N in that background; Vm  80 mV. B: Open probabilities of the constructs in
A (see color coding) during the last 4 min of each 5-min ATP-free segment of recording. C: Thermodynamic
mutant cycle illustrating mutation-induced changes in GO-C (numbers next to arrows); Gint(O-C) is the
difference beween GO-C values along two parallel sides of the cycle. The four corners of the cycle are
represented by the pairs of residues present at positions 555 and 1246, respectively. D: Cartoon depicting
mechanism of spontaneous openings. Color coding as in FIGURE 1A; the R domain is not depicted. [Adapted
with permission from Mihályi et al. (160)].
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coupling between slow gating andNBD dimerization/disso-
ciation seems to be an intrinsic property of the CFTR pro-
tein; ATP binding alters the energetics, but not the basic
structural organization, of the open- and closed-pore con-
formations. The similar structural architecture of ATP-free
and ATP-bound open states also readily explains correlated
and additive effects on spontaneous and ATP-driven chan-
nel activity of the various allosteric modulators mentioned
above [R domain phosphorylation, TMD mutations, or
drug binding to TMDs (253)] through energetic stabiliza-
tion or destabilization of the inherent open-state structure.
A similarity between ATP-free and ATP-bound open chan-
nel structures is also consistent with inhibition of opening
of disease mutant G551D CFTR by ATP binding at site 2,
interpreted to reflect electrostatic repulsion between the
negative charge of the aspartate in the site 2 signature se-
quence and that of the -phosphate of ATP bound to the site
2 Walker motifs (133). Because electrostatic interactions
are very short range in water, such an interaction would not
be expected to occur if the site 2 interfacial NBD surfaces
did not approach each other and become dehydrated (i.e., if
the dimer interface did not close) in the G551D mutant
upon pore opening, but it is plausible if pore openings re-
main strictly coupled to NBD dimerization. Indeed, the as-
partate side chain in position 551 does not sterically inter-
fere with closure of the dimer interface, because introduc-
tion of large uncharged (serine) or positive (lysine) side
chains are tolerated here (133). Although infrequent ATP-
independent pore openings of NBD2 CFTR (248) can
clearly not be linked to NBD dimerization, it seems likely
that upon pore opening, its remaining NBD/TMD coupling
machinery undergoes movements similar to those that ac-
company NBD dimerization in full-length CFTR.
E. Strictness of Coupling Between Open
Burst Termination and ATP Hydrolysis
How strictly CFTR gating is coupled to ATP hydrolysis has
been a matter of longstanding debate. The first hint imply-
ing a nonequilibrium gating cycle came from the observa-
tion of time-asymmetric changes in permeation properties
in patch-clamp records of individual gating CFTR channels
(96). The kinetics of pore block ofWTCFTR by the anionic
buffer MOPS changes within each burst, a phenomenon
that can be made evident by the presence, at small recording
bandwidth, of two distinct conductance states (one low,
one high) (109). The sequence of occurrence of these con-
ductance states shows clear time asymmetry; the ratio be-
tween resolvable low-to-high (L¡H) and high-to-low
(H¡L) transitions is ~16:1 (96), with the majority of time
during each burst spent in the initial low-conductance state.
Such time asymmetry is a clear violation of microscopic
reversibility and indicated strong coupling between pore
gating and a free-energy releasing process, here, most likely
ATP hydrolysis. Indeed, the L¡H transition itself was sug-
gested to coincide with ATP hydrolysis, because it was ab-
sent under nonhydrolytic conditions (96). In apparent con-
flict with that conclusion of strong coupling, mutation of
the NBD1Walker A lysine (K464A) reduced ATPase activ-
ity of purified CFTR protein by ~10-fold but little affected
channel gating, interpreted to suggest loose coupling be-
tween gating and catalytic activity in CFTR (192).
In single-channel recordings, transitions among closed-
channel states, or among open-channel states, remain un-
detected. However, such invisible transitions contribute to
determining the shapes of the open– and closed–dwell time
distributions (which consist of mixtures of exponential
components), making it possible to estimate their rates
through maximum likelihood fitting (50). For equilibrium
processes, the fractional amplitude of each exponential
component is necessarily positive, and the distributions are
therefore monotonically decaying (117). In contrast, for
WT CFTR, the distribution of open burst durations is
clearly peaked (FIGURE 5A). This experimental observation
thus reveals an underlying nonequilibrium gating mecha-
nism, with most open events involving two sequential steps:
a slow stepwith a rate of ~4 s1, followed by a fast stepwith
a rate of ~50 s1 (at room temperature) (61). These two
sequential steps were interpreted to reflect slow ATP hydro-
lysis (FIGURE 2E, step O1¡O2, rate k1) followed by fast
disruption of the posthydrolytic NBD dimer (FIGURE 2E,
step O2¡C2, rate k2). Indeed, the rate-limiting step for WT
CFTR channel closure is strongly temperature dependent,
with an estimated activation enthalpy H‡~70–90 kJ/mol
[(57, 155) but, cf., (6)], and the similar values for G‡ and
H‡ report no decrease in entropy (57). Such an isolated
positive enthalpy change, unaccompanied by a change in
entropy, is consistent with strain in a single chemical bond
without accompanying changes in interface accessibility to
solvent molecules. These observations suggest that the ATP
hydrolysis step (O1¡O2) is rate limiting for channel clo-
sure; the transition state for this step would include a still
tightly dimerized composite site 2 but a strained bond be-
tween the  and  phosphates of the occluded ATP.
Because in WT CFTR the rate of nonhydrolytic closure
(FIGURE 2E, step O1¡C1, rate k1) is likely very slow, esti-
mated between ~0.03 and 0.2 s1 based on the slow closing
rates of various nonhydrolytic mutants, 95% of pore
opening events must terminate through ATP hydrolysis,
consistent with the conclusions of Gunderson and Kopito
(1995) (94%). In contrast, the burst distribution of the
nonhydrolytic D1370N mutant lacks a negative exponen-
tial component and is monotonically decaying (FIGURE 5B),
reflecting a gating cycle truncated to reversible C1↔O1
transitions (61), with rate k1 (~0.5 s
1) accelerated by this
mutation, which removes a side chain involved in Mg2
coordination (269). On the other hand, fitting the burst
distribution of the site 1 mutant K464A (FIGURE 5C) sug-
gested an approximately fourfold reduction in rate k1 (i.e.,
allosteric slowing of ATP hydrolysis in site 2) and a 10-
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fold acceleration of rate k1 (61), consistent with the effect
of this mutation on macroscopic closing rates in various
nonhydrolytic mutant backgrounds (56, 61, 185, 243).
Thus, the coupling ratio that quantifies the proportion of
pore opening (burst) events that result in ATP hydrolysis
[given by k1/(k1 k1) for the scheme in FIGURE 2E (i.e., the
ratio of the rate of hydrolysis over the sum of all rates out of
the prehydrolytic open state)] may be lowered by mutations
that slow ATP hydrolysis and/or accelerate nonhydrolytic
dissociation of the NBD dimer; it is 0.95 for WT CFTR
(strong coupling), but only ~0.2 for K464A (loose coupling)
and 0 for nonhydrolytic mutants (no coupling) (FIGURE 5D,
colored arrows). Such an interpretation is consistent with
the ATPase measurements of Ramjeesingh and colleagues
(1999) on both WT CFTR and the two Walker A lysine
mutants.
More recently, time-asymmetric subconductance patterns
(L¡H) for single CFTR channels have been observed in the
presence of the blocker 3-nitrobenzoate (60) as well as in
mutants in which the native charge distribution of the in-
tracellular pore vestibule is perturbed (113, 272). Intrigu-
ingly, for the latter mutants, multiple L¡H subconduc-
tance transitions could be observed in ~10–20% of the
bursts. On the assumption that L¡H transitions reflect
ATP hydrolysis events, L¡H¡L¡H type bursts were in-
terpreted to reflect two ATP hydrolysis events occurring
within a single burst [i.e., a coupling ratio  1 (“super-
coupling”)]. The phenomenon was explained by a model
that postulates that the hydrolysis products ADP  Pi may
be released, and a novel ATP molecule may bind at site 2,
returning the channel to the prehydrolytic open state with-
out an intervening pore closure (113). The existence of such
a reentry pathway, which implies separation of the NBD
dimer interface around site 2 uncoupled from pore closure,
seemed consistent with the earlier finding that a brief, 1-s
exposure of open CFTR channels to PPi or AMPPNP in the
presence of ATP, or immediately after ATP removal, can
lock CFTR channels into a long-lasting burst without an
intervening long closure. It also seemed consistent with the
modest [ATP] dependence of steady-state single-channel
burst durations observed for W401F (but not for WT)
CFTR (114). Moreover, the CFTR potentiator drug VX-
770 (ivacaftor) was shown to increase the frequency of
L¡H¡L¡H-type bursts and to prolong CFTR burst du-
rations in a weakly [ATP]-dependent manner, prompting
the interpretation that the drug acts by stabilizing the post-
hydrolytic O2 state and thus promoting the reentry path-
way (112).
A major shortcoming of the reentry model is that it predicts
a dissociation between the steady-state mean burst duration
(b) and the time constant of macroscopic current relax-
ation following sudden nucleotide removal (relax). This is
FIGURE 5. Distributions of CFTR burst
durations support nonequilibrium gating.
A–C: Distributions of burst durations for
prephosphorylated wild-type (WT) (A),
D1370N (B), and K464A (C) CFTR chan-
nels gating in 2 mM ATP at 25°C. Solid red
lines in A and C are maximum likelihood fits
to the scheme in panel D; in A, rate k1
was fixed to zero. Dotted blue lines in A–C
are maximum likelihood fits to a nonhydro-
lytic equilibrium C1↔O1 scheme. Fitted
rates are printed in the panels. Insets show
30-s segments of single-channel inward
currents; Vm  80 mV. D: Cartoon gat-
ing cycle illustrating coupling ratios. Col-
ored vertical and horizontal arrows and
numbers depict fractions of bursts termi-
nated through ATP hydrolysis and nonhy-
drolytic NBD dimer dissociation, respec-
tively, for WT (blue), K464A (red), and
D1370N (green) CFTR. [Adapted with per-
mission from Csanády et al. (61)].
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because the latter reflects average survival time in the open
burst state at zero nucleotide concentration (i.e., in the cer-
tain absence of reentry events). Thus, for a channel that
gates at steady state, the average number of site 2 nucleotide
occlusion events within a single burst is given by the ratio
b/relax; that number was found to be ~1 under most, if not
all, conditions tested, includingWT CFTR and various mu-
tants gated by either ATP or N6-(2-phenylethyl)-ATP (P-
ATP) (56, 233) and even for WT CFTR stimulated by VX-
770 (112). On the other hand, both [ATP] dependence of b
and the existence of L¡H¡L¡H-type bursts might be ac-
counted for by alternative explanations. First, b depen-
dence on [ATP] might arise from a differential contribution
to channel activity of spontaneous openings. CFTR chan-
nels are known to open with ATP bound at only one compos-
ite site (25, 26, 185) and occasionally even in the complete
absence of nucleotide (25, 160, 224, 253). Suchmonoliganded
and unliganded (spontaneous) openings are briefer than nor-
mal diliganded openings (160, 257), and their fractional
contribution, which shortens mean burst duration, is ex-
pected to be stronger at low [ATP]. Although forWTCFTR
this effect is too subtle to be measurable in most studies
[(24, 112, 243); but cf., (270)], it might be accentuated by
mutations that perturb ATP binding at either site (114) or
by drugs that increase the frequency of spontaneous open-
ings, such as VX-770 (112). Second, how might
L¡H¡L¡H-type bursts arise? L¡H subconductance
transitions are believed to coincide with ATP hydrolysis
because only the L state is readily observed under nonhy-
drolytic conditions (e.g., in the absence of Mg2, in the site
2 mutants D1370N, K1250A, and E1371S, or for WT
channels locked open by ATP  PPi or ATP  AMPPNP),
(96, 113). However, in ABC proteins, splitting of the ATP
- bond is a multi-step process, as evidenced by multiple
intermediate states distinguishable by blocking the hydro-
lysis reaction using ATPS, Vi, fluoroaluminate, beryllium
fluoride, or different catalytic site mutations (213, 222,
236). Which of these partial steps coincides with the L¡H
transition is as yet unclear; some of these might be revers-
ible, and so repeated L¡H transitionsmight reflect multiple
attempts to complete the bond-splitting reaction. Alterna-
tively, the entire ATP hydrolysis process (step O1¡O2; FIG-
URE 2E) might be reversible; although the ATP hydrolysis
reaction with reagents and products in aqueous solution is
highly exergonic, in a multi-step enzymatic process, that
starts with binding of ATP(aq) from the bulk solution and
ends with the release of products [ADP(aq)  Pi(aq)] into
solution, the step associated with the largest negative Go
need not be the bond-splitting step itself. Thus, Go for the
reaction (CFTR · ATP)H2O¡CFTR · ADP · P, in which
reagents and products are bound within the catalytic site,
might not be highly negative [cf., ATP- and ADP · P–bound
states of the F1-ATPase  subunit are in equilibrium (264)].
Of note, reversibility of stepO1¡O2 (FIGURE 2E)would not
alter the shape of the burst dwell time distributions (61). As
a third possibility, coupling between conductance state and
hydrolytic state might be only probabilistic, such that the
prehydrolytic state (O1, FIGURE 2E) only favors (but is not
strictly linked to) the lower conductance (L), whereas the
posthydrolytic state (O2, FIGURE 2E) favors (but is not
strictly linked to) the higher-conductance (H) pore confor-
mation. None of these possible alternatives has been ex-
cluded to date.
Where this has been studied, both ATP-dependent (242)
andATP-independent (160) open channels have been found
to have tightly dimerizedNBDs, with ATP at site 2 occluded
(see Section IVD). Given this evidence and the consider-
ations above on our uncertainty on how to precisely link the
conductance changes to events at the catalytic site, the con-
formational changes underlying the L¡H transition are
more easily interpreted as changes in the TMDs that do not
alter tight NBD dimerization. As described above (Section
IIC), structures for a number of ABC transporters have been
obtained in outward-facing conformations (46, 67, 256) in
which the extracellular portions of the TMDs, correspond-
ing to the regions involved in forming CFTR’s permeation
pathway, assume diverse arrangements, whereas the NBDs
remain tightly dimerized. Thus, CFTR’s low conductance
state might represent a conformation in which, as in the
phosphorylated ATP-bound zebrafish CFTR structure
(274) or theMcjD transporter (46), the extracellular ends of
the TMhelices are arranged in a largely parallel orientation,
whereas the high-conductance conformation reached at the
end of the burst might be somewhat more similar to the
Sav1866 structure (67) in which the extracellular ends of
the TM helices further diverge. Of note, the position corre-
sponding to R352 in human CFTR, mutations at which
appear to differentially affect conductance in the O1 andO2
state (113), is positioned at a constriction of the permeation
pathway in Sav1866-based homologymodels (52, 163), but
in the wider intracellular vestibule in the outward-facing
zebrafish CFTR structure (274) and in models based on
McjD (52).
F. Role of the Degenerate ATP-Binding Site
in Channel Gating
Photocrosslinking experiments using [32P]8-azido-ATP to
label the two ATP sites, and various unlabeled nucleotides
to compete that labeling, identified site 1 as a high-affinity
binding site with a Kd for Mg-ATP in the low micromolar
range (7, 14). Furthermore, labeling of site 1 by [32P]8-
azido-ATP, without cross-linking, was shown to survive
several minutes of extensive washing with nucleotide-free
solution at 30°C, demonstrating poor or absent catalytic
activity at the degenerate site (14). Given that the cycle time
for channel gating is on the order of ~1 s, these biochemical
findings suggested that site 1 must keep ATP bound but
unhydrolyzed throughout many gating cycles, in contrast to
site 2, which hydrolyzes ATP within each channel burst
event. Indeed, such an asymmetry between the kinetics of
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nucleotide exchange in the two sites was supported by li-
gand exchange experiments in which ATP and the high-
affinity analog P-ATP were intermittently applied to inside-
out patches. Gating of CFTR channels in P-ATP is charac-
terized by approximately twofold prolonged bursts (slower
closing) and approximately twofold shortened interbursts
(faster opening), as compared with gating in ATP. How-
ever, whereas the effect on opening rate (attributed to the
nucleotide bound in site 2) is observed instantaneously
upon exchange of the bath nucleotide, the effect on closing
rate (attributed to the nucleotide bound in site 1) appears
with a delay of ~50 s (233).
What is the extent of gating-related movements in site 1? In
closed channels, the NBD dimer interface must disengage
occasionally even around site 1, because, albeit slowly, the
nucleotide in site 1 can be clearly exchanged (233) and that
is most unlikely to happen while the interface is tight. But to
what extent, and how frequently, does site 1 open up? The
slow nucleotide exchange rate at site 1 is affected by NBD2
signature sequence (S1347) mutations (233), suggesting
that the NBD2 tail continues to contribute to ATP binding
even while the pore is closed. In apparent contradiction to
these findings, cysteines engineered into the signature sequence
at either site 1 (S549C) or site 2 (S1347C) were accessible to
small hydrophilicmethanethiosulfonate (MTS) reagents in the
closed, but not in the open state, and were modified equally
rapidly at a rate approximating the rate of pore closure. Thus,
upon pore closure, the NBD interface must open up around
both ATP sites promptly and sufficiently to accommodate re-
agents with a diameter up to ~8 Å (37). A heterodimeric bac-
terial ABC transporter, Tm287–288, crystallized in the pres-
ence of AMPPNP, shows an inward-facing conformation
(101) with nucleotide bound only at site 1, but with both
binding sites partially open (i.e., Walker A and signature se-
quences are separated and accessible to the solvent and to
relatively large reagents). Some contact across the site 1 inter-
face is maintained through interactions between theWalker A
loop of NBD1 and the D-loop of NBD2. In particular, the
residues corresponding to CFTR’s T460 inNBD1 andH1375
in NBD2 are seen to form hydrogen bonds. Maintained con-
tact between these two residues, throughout CFTR’s gating
cycle, is supportedby lackof gating-associated changes in their
energetic coupling (223). One possible interpretation, consis-
tent with both MTS accessibility (37) and mutant cycle (223)
studies, is that closing of the pore corresponds to a partial
opening of site 1, as seen in the Tm287–288AMPPNP-bound
crystal. However, functional studies on Tm287–288 (230),
as well as on SUR1/KATP (176) and CFTR (243) channels,
suggest that binding of AMPPNP to heterodimeric ABC
proteins has a poor efficacy in altering equilibria toward the
NBD-dimerized conformations. Thus, bound Mg-ATP
might be more effective in maintaining the site 1 interface
tightly dimerized, even immediately after pore closure, as
the nucleotide exchange studies would suggest (233). One
possible unifying interpretation could be that there is a
rapid equilibrium between a tightly dimerized and a par-
tially open conformation of site 1 in closed channels:
whereas the impact of NBD2 signature sequence mutations
on site 1 nucleotide exchange rate (233) depends on the
fraction of time a closed channel spends with site 1
dimerized, the rate of MTS modification of site-1 cysteines
upon pore closure (37) reflects the rate of first passage to the
dedimerized state. Thus, possibly in a closed channel, site 1
might remain in a dimerized state for most of the time but
nevertheless visit the dedimerized state frequently enough
to allow high-probability modification of site 1 cysteines
within a single closed-channel (interburst) event. Under-
standing the precise range of gating-related movements in
CFTR’s site 1 will require a high-resolution structure of
phosphorylated CFTR in a closed state with ATP bound at
site 1.
What role does site 1 play in CFTR channel gating? Regard-
less of what the precise spatial arrangement of the most
frequently populated closed-channel conformation is, sig-
nificant rearrangements must occur in site 1 between that
conformation and the open-channel conformation, because
site 1 structural perturbations clearly alter the free energy
difference between the ATP-saturated closed-pore (FIGURE
2E, C1) and the prehydrolytic open-pore (FIGURE 2E, O1)
states (56, 185, 281). But whereas in canonical site 2 the
conformational changes upon pore opening are completed
already in the transition state, as reported by its large 
value of ~1 (FIGURE 3A, right, red numbers), for degenerate
site 1, the low  value of ~0.4 (FIGURE 3A, right, orange
numbers) reports some further motion between the transi-
tion state and the open state. ATP stabilizes the open-pore
conformation by acting as a molecular glue that bonds the
NBD dimer interface together. Comparison of gating kinet-
ics of ATP hydrolysis–deficient mutants in saturating ATP
and of WT CFTR channels in the absence of ATP (sponta-
neous gating) indicates that the presence of bound ATP
both speeds channel opening (FIGURE 2E, step C1¡O1) and
slows nonhydrolytic closure (FIGURE 2E, step O1¡C1)
(160). The effect on opening rate is readily explained by the
bonding of the ATP glue in site 2, which is already com-
pleted in the transition state (FIGURE 3B, bottom site, red
cups around ATP in states T and O1); that glue stabilizes
state T (and O1) relative to state C, thereby lowering the
energetic barrier for opening. However, slowing of nonhy-
drolytic closure indicates that ATP binding also stabilizes
the open state (O1) relative to the transition state (T) (i.e.,
ATP-bound channels, compared with spontaneously
opened channels, face a higher energetic barrier to closing
by simple reversal of the opening step). Indeed, the move-
ments in site 1 that occur between the transition state and
the open state might reflect the bonding of the ATP glue in
the degenerate site (FIGURE 3B, top site, red cups around
ATP in state O1), which underlies this differential stabiliza-
tion of O1 compared with T. In the context of ATP-
dependent gating of WT CFTR (FIGURE 2E), that bonding
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effect of ATP in site 1 would explain the small value of rate
O1¡C1, which ensures strictly unidirectional, nonequilib-
rium cycling (FIGURE 2E, purple circular arrow; cf., FIGURE
5D). Consistent with such an interpretation, channel closure
under nonhydrolytic conditions is affected by a number of
structural perturbations in site 1; it is accelerated by the
K464A mutation (56, 185, 243) or by deletion of the RI
(54) but slowed by the H1348A mutation (56) or by P-ATP
bound in site 1 (56, 233).
G. The Channel-Transporter Interface: CFTR
Viewed as a Degraded Active Transporter
From an evolutionary perspective, CFTR is most closely
related to the exporter class of ABC proteins that extrude a
variety of substrates, against their electrochemical gradi-
ents, out of cells. To avoid instantaneous dissipation of the
electrochemical gradient built up at the expense of ATP
hydrolysis, exporters must have two gates, and these must
never be open at the same time (83). In the inward-facing
conformation of ABC exporters, a closed outer gate is
formed by the converging external ends of the TM helices
(8, 101, 212, 256), whereas in the outward-facing confor-
mation, tight bundling of the cytosolic ends of the TM
helices forms a closed inner gate (46, 67, 256). The inward-
facing conformation thus allows high-affinity substrate
binding from the cytosolic side, whereas in the outward-
facing conformation, the substrate is released into the ex-
tracellular medium. The inward- to outward-facing confor-
mational transition is driven by NBD dimerization follow-
ing ATP binding (146). However, unidirectional uphill
transport requires a source of external energy input. That
energy source, the binding and hydrolysis of ATP, is har-
nessed to drive conformational changes unidirectionally,
thus switching the substrate binding site from inward-fac-
ing high affinity to outward-facing low affinity in the loaded
transporter and allowing release of substrate even in the
face of a high extracellular concentration (13).
Based on the common evolutionary origin of CFTR and
ABC exporters, and on the finding that, in CFTR, dimerized
NBDs are coupled to an open, but dedimerized NBDs to a
closed, pore (242); CFTR’s TMDs were believed to adopt
an inward-facing conformation in the closed (interburst)
but an outward-facing conformation in the open (burst)
state. Because the latter conformation forms a transmem-
brane aqueous pore permeable to anions, in CFTR, the ABC
protein internal gate was proposed to have become “leaky”
to anions over the course of evolution. Supported by a line
of functional evidence (12, 64, 107, 252), that proposal was
finally proven to be correct by the recent structures of in-
ward- and outward-facing CFTR [(145, 273, 274); FIGURE
1E–F]. These structures also identify the structural changes
that implemented CFTR’s evolution from a transporter to a
channel; the appearance of a lateral opening between the
cytosolic ends of TM helices 4 and 6 (FIGURE 1F, right, red
arrow) provides an aqueous pathway between the cytosol
and the internal vestibule, thus short-circuiting the ABC
protein internal gate formed by the cytosolic TM helix bun-
dle crossing [cf., (76, 77)]. But why has the ATP hydrolysis-
driven, nonequilibrium gating cycle of CFTR been spared
by evolution? The passive, electrochemically downhill chlo-
ride ion flow through CFTR could, in principle, be con-
trolled by simple ATP binding (i.e., reversible C1↔O1 tran-
sitions, see FIGURE 2E) without any need for “wasteful”
ATP hydrolysis. A likely explanation is a lack of evolution-
ary pressure given that ATP wasting by CFTR is negligible,
because P-type ATPases like the ubiquitous Na-K-
ATPase transport only ~5 cations at the expense of hydro-
lysis of a single ATP molecule, whereas CFTR transports
millions of chloride ions at the same cost. Alternatively, in
addition to serving as an anion channel, CFTR might also
serve as an active transporter of some, as yet unidentified,
substrate. Interestingly, CFTR was found to mediate efflux
of large organic anions, such as gluconate or lactobionate
(142), or of reduced and oxidized glutathione (143) from
the cytosolic solution but not influx of the same anions from
the extracellular solution; this asymmetry was disrupted
when ATP hydrolysis was prevented, using PPi or AMP-
PNP. However, the molecular mechanism of such ATP hy-
drolysis–dependent unidirectional export is still elusive; it is
not a classical transporter-like process, as the estimated
throughput rate for gluconate export [~40 fA, correspond-
ing to ~2.5 	 105 ions/s (142)] exceeds measured rates of
ATP hydrolysis [~1 ATP/s (131, 145)] by five orders of
magnitude.
H. Adenylate Kinase Catalytic Activity and
Gating Regulation
Isolated, purified NBD1 and NBD2 of CFTR showmeasur-
able adenylate kinase (AK) activity, catalyzing reversible
interconversion between ATP  AMP and two ADP mole-
cules by direct phosphotransfer between the two nucleo-
tides (93, 193, 194). Based on this finding, CFTR was sug-
gested to catalyze preferentially AK, rather than ATPase
reactions, in the presence of AMP levels found in living cells
(195). Along these lines, partial inhibition of CFTR channel
currents by ADP or the AK inhibitor P1,P5-di(adenosine-
5=)pentaphosphate (AP5A), as well as subtle effects of AMP
on currents evoked by low micromolar ATP, were all inter-
preted to reflect alterations in CFTR gating caused by mod-
ulation of its intrinsic AK activity (195, 197). However,
unlike the purified isolated NBDs, full-length CFTR protein
purified to homogeneity was shown to exhibit exclusively
ATPase, but no significant AK, activity (193). As the ATP-
ase turnover rate of the same preparation was comparable
with that of channel bursting rates (~0.2 s1), intrinsic AK
activity of full-length CFTR, if any, would be expected to be
orders of magnitude slower than channel gating rates; in-
deed, even for isolated NBDs, reported AK turnover rates
were in the range of 0.003–0.02 s1 [(193, 195); but, cf.,
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(93)]. Interestingly, recent studies demonstrated phospho-
ryl transfer between -32P-GTP and 2-azido-AMP (2-N3-
AMP) in membrane preparations of CFTR-overexpressing
HeLa cells, and the resulting -32P-2-N3-ADP product
could be photocrosslinked to CFTR; moreover, that signal
was weakened by CFTR site 2 mutations S1248F (196) and
Q1291F (70). These results could indeed reflect some intrin-
sic AK activity for CFTR, but they could also be explained
by the activity of an endogenous AK associated with HeLa
cell membranes; reduced labeling of the CFTR mutants
could then reflect impaired binding to CFTR’s site 2 of the
labeled -32P-2-N3-ADP produced by the associated AK.
Indeed, AK1 contains a myristoylation domain and has
been shown to strongly associate with membranes (49). AK
also interacts with multiple enzymes involved in energy ho-
meostasis, and at least two AK anchoring proteins have
been identified [reviewed in (73)]. Specifically, AK1 directly
interacts with sarcolemmal KATP channels, as demonstrated
by mutual coimmunoprecipitation and AK-mediated regu-
lation of KATP channel activity, implying strong structural
and functional coupling between the two proteins (31).
Thus, a definitive proof of intrinsic AK activity for CFTR
will require demonstration of such activity for full-length
CFTR protein under conditions that exclude the presence of
associated cellular proteins.
Modulation of CFTR currents by various nucleotides and
nucleotide analogs has been addressed by multiple studies
and ismostly consistent with competitionwith ATP for sites
1 and 2 [e.g., (24, 25, 195, 203, 258)]. At least the strong
inhibitory effect of ADP, caused by a slowing of channel
opening and an acceleration of channel closing (24, 203,
258), is readily explained by competition with ATP for sites
2 and 1, respectively (24, 25), and cannot be linked to AK
activity of CFTR, as both effects are observed also for
CFTR channels bearing site 2 mutations K1250A or
D1370N (25) shown to abolish AK activity even for iso-
lated NBD2 of CFTR (93, 195). Likewise, inhibition by
AP5A of ATP-induced CFTR currents cannot be attribut-
able to inhibition of AK activity because it is observed in the
absence of AMP (i.e., in inside-out patches continuously
superfused with solutions that contain ATP, but no AMP)
(195).
V. REGULATION OF CFTR GATING BY R
DOMAIN PHOSPHORYLATION
A. Kinases and Phosphatases Involved in
CFTR Regulation
Cytosolic ATP is essential for CFTR channel gating, but
ATP concentration cannot serve as a physiological regula-
tor of channel activity; because the K1/2 for stimulation of
open probability by ATP is ~50 M, CFTR channels are
saturated by the millimolar ATP concentrations present in
the cytosol of living cells. ATP-dependent gating is therefore
regulated through phosphorylation/dephosphorylation of
the CFTR protein. PKA, the key regulator of CFTR activity,
phosphorylates multiple R domain serines found in consen-
sus motifs, a process essential for channel gating (9, 20). In
addition, several other kinases have been identified that
affect CFTR function. CFTR phosphorylation by protein
kinase C (PKC) was shown to cause partial current activa-
tion (21, 225), and basal PKC phosphorylation of some
CFTR residue(s) was claimed essential for subsequent full
channel activation by PKA (35, 111). In vitro studies using
an R domain peptide identified R domain serines 686 and
790 as the target sites for PKC phosphorylation (183).
AMP-activated protein kinase (AMPK) binds to the
COOH-terminus of CFTR and phosphorylates the CFTR
protein in vitro (98), and coexpression of AMPK with
CFTR in Xenopus laevis oocytes (98) or pharmacological
activation of endogenous AMPK in a lung epithelial cell line
(97) lower whole-cell CFTR currents. Tyrosine kinases, in-
cluding p60c-Src and the proline-rich tyrosine kinase 2
(Pyk2), are both capable of activating CFTR currents (22,
81), and such activation is prevented by simultaneous mu-
tation of two tyrosines at positions 625 and 627, implicat-
ing the latter residues as likely tyrosine kinase substrates
(23). CaM kinase I was also found to phosphorylate a
CFTR R domain peptide in vitro (183), but no effects on
channel activity have so far been demonstrated (21).
cGMP–dependent protein kinase isoforms have also been
found to phosphorylate CFTR, an activity that is likely to
play a role in the action of heat-stable enterotoxins during
secretory diarrheas (82) and possibly in CFTR current ac-
tivation by S-Nitrosoglutathione in an airway cell line (41).
In particular, isoform II (cGKII) isolated from pig intestines
was shown to phosphorylate the R domain with patterns of
two-dimensional peptide mapping similar to PKA, and to
result in activation of CFTR channels in heterologous ex-
pression systems and in an intestinal cell line (82).
Several phosphatases have been tested for their effectiveness
in dephosphorylating CFTR. Whereas phosphatases 1
(PP1) and 2B (PP2B, calcineurin) little affect currents of
prephosphorylated CFTR [(21, 149); but, cf., (80)], phos-
phatases 2A (PP2A) (21, 149) and 2C (PP2C) (149, 232)
have both been shown to efficiently deactivate CFTR chan-
nels in inside-out patches. The relative contribution of these
two phosphatases to CFTR regulation in vivo is likely cell
type specific. Among exogenous phosphatases frequently
used for in vitro studies, alkaline phosphatase does not
affect CFTR activity (21), whereas lambda phosphatase de-
activates CFTR (81) and abolishes detectable phosphoryla-
tion of CFTR protein purified from resting cells (145).
B. Target Sites of PKA
PKA phosphorylates serines and threonines of target pro-
teins found in consensus motifs of the form R-R/K-X-S/T
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(dibasic sites) or R-X(-X)-S/T (monobasic sites), with a
preference for dibasic motifs (116). The R domain sequence
in CFTR (a.a. ~640 to ~840) contains nine dibasic and
several monobasic PKA consensusmotifs; a further serine in
a dibasic motif, S422, localizes to the RI segment of NBD1.
Out of this pool of potentially phosphorylatable residues a
large number of studies have identified at least nine posi-
tions that are phosphorylated by PKA either in vivo or in
vitro (TABLE 1). Although found in a dibasic motif, serine
686 was not seen to be phosphorylated by PKA, but instead
was found to be a substrate for PKC (183). To our knowl-
edge, phosphorylation by PKA of threonine 788, located in
a dibasic motif, has not yet been demonstrated.
Under in vitro conditions gradual phosphorylation of an R
domain peptide by PKA causes incremental electrophoretic
mobility shifts, allowing visual discrimination of up to six
distinct phosphoforms that appear with different kinetics
(FIGURE 6A). Two-dimensional peptide mapping and mass
spectrometric analysis of the phosphoforms revealed that
phosphorylation of serine 737 causes the largest mobility
shift, and identified serine 768 as being among the first to
become phosphorylated (58, 183).
C. Stimulatory and Inhibitory
Phosphorylation Sites
In inside-out patches, in the presence of saturating ATP but
various concentrations of the active catalytic subunit of
PKA (FIGURE 6B), the steady-state open probability of sin-
gle CFTR channels shows a roughly hyperbolic dependence
on PKA concentration [(58); FIGURE 6C, red symbols]. Be-
causemembrane-associated endogenous phosphatase activ-
ity is independent of the amount of applied kinase, at steady
state the R domain is expected to become phosphorylated to
a higher stoichiometry when the applied PKA concentration
is higher. The implication is that channel open probability is
not regulated in an all-or-none fashion by PKA, but is rather
roughly proportional to the degree (stoichiometry) of R
domain phosphorylation. Thus, most PKA target serines
might be classified as “stimulatory PKA sites.” Accordingly,
mutation to alanine of four, eight (199), or ten (34) consen-
sus serines substantially reduced channel open probability
in the presence of ATP and PKA. Surprisingly, however,
even channels lacking all 10 serines located in dibasic PKA
sites retain substantial phosphorylation-dependent channel
activity with a maximal open probability almost 50% of
that of WT CFTR (154), implying large functional redun-
dancy among PKA target serines. Just as different PKA tar-
get sites are phosphorylatedwith different kinetics, the rates
of dephosphorylation of individual phosphoserines by
membrane-associated endogenous phosphatases are likely
diverse; in inside-out patches excised from various cell
types (9, 55, 250), macroscopic CFTR currents decline
with a biexponential time course following sudden re-
moval (or inhibition) of PKA (FIGURE 6D). An initial
rapid partial current decline (within seconds) is followed
by a much slower decay (over minutes), suggesting the
existence of a relatively stable, partially phosphorylated
state of CFTR distinguishable from the fully phosphory-
lated state by approximately two- to threefold shorter
mean burst durations and approximately twofold longer
interburst durations (55).
Whereas alanine replacement of most PKA target serines
negatively affects channel activation, mutation of serines
737 and 768were found to increase the sensitivity of whole-
cell CFTR currents toward activation by 3-isobutyl-1-
methylxanthine (IBMX), which activates endogenous PKA
by elevating cellular cAMP levels (260). Classification of
serines 737 and 768 as inhibitory PKA sites was further
supported by slightly and robustly elevated open probabil-
ities, respectively, of S737A and S768A CFTR channels in
inside-out patches [(237); but, cf. (100)]. The S768A muta-
tion increases the sensitivity for channel activation by PKA,
resulting in substantial CFTR currents already at the low
endogenous PKA activity of resting, unstimulated cells but
also increases maximal open probability (FIGURE 6C, blue
symbols), mainly by lengthening mean burst durations.
These effects appear to be direct effects on channel gating,
as the kinetics and degree of phosphorylation of other PKA
target serines remain largely unaffected in the mutant (58,
100). The in vivo relevance of inhibitory CFTR regulation
might be twofold. First, by shifting the PKA dose response
Table 1. CFTR positions phosphorylated by PKA in vivo or in vitro
Positions In Vitro/In Vivo Reference
660 700 712 737 768 795 813 CFTR in vitro 43
660 737 795 813 CFTR in vivo 43
660 700 737 768 795 813 CFTR in vitro 183
753* CFTR in vitro 206
422 660 700 712 737 768 795 813 NBD1-R in vitro 231
660 700 712 737 753* 768 795 813 CFTR in vitro 168
660 700 712 737 768 795 CFTR in vivo† 58
*Monobasic site. †Resting Xenopus laevis oocytes.
CSANÁDY ET AL.
726 Physiol Rev • VOL 99 • JANUARY 2019 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (193.224.049.128) on January 15, 2019.
curve to the right, phosphorylation of serine 768 by PKA,
already detectable at basal PKA activity levels, might
dampen the WT CFTR current response to low levels of
PKA stimulation (FIGURE 6C). Second, serine 768 was also
identified as the target site for phosphorylation by inhibi-
tory AMPK (119, 123), so its phosphorylation might rep-
resent a mechanism to adjust CFTR activity to the meta-
bolic state of the cell.
D. Molecular Mechanism of Gating
Regulation by Phosphorylation
PKA-dependent regulation of CFTR activity can be largely
ascribed to an inhibitory influence of the unphosphorylated
R domain on channel gating, which is relieved upon phos-
phorylation. Whereas unphosphorylated WT CFTR chan-
nels show negligible open probability, a construct in which
a large part (a.a. 708–835) of the R domain is deleted (R
CFTR) is substantially active without phosphorylation
(200). Similarly, deletion of the entire R domain (a.a. 634–
836) by coexpression of CFTR segments 1–633 and 837–
1480 (cut–R CFTR) yields channels that are active before
phosphorylation, whereas channels merely split in two, but
still containing the R domain, obtained by coexpression of
CFTR segments 1–633 and 634–1480, remain strictly reg-
ulated by PKA (55).
In addition to loss of an inhibitory effect, a direct stimula-
tion of channel gating by the phosphorylated R domain also
seems to contribute to the full gating response of CFTR to
PKA, as unphosphorylated R CFTR is slightly stimulated
by superfusion with a phosphorylated R domain peptide
(150, 262). Accordingly, open probability of unphosphor-
ylated cut–R CFTR is somewhat lower than that of fully
phosphorylated split channels containing the R domain
(55). Quantitative analysis suggests that disinhibition ac-
counts for ~50-fold, whereas direct stimulation by the phos-
phorylated R domain accounts for an additional approxi-
mate twofold increase in open probability, amounting to an
~100-fold total enhancement of WT CFTR channel cur-
rents by PKA (54).
In search for the biophysical mechanism that underlies the
regulatory effect of the R domain, a number of observations
have been made. Pull-down assays documented phosphory-
lation-dependent interactions of the R domain with other
parts of the channel (29, 36), including the lasso motif (FIG-
URE 1E, red), which is located at CFTR’s cytoplasmic NH2
terminus (166) and has been shown to also act as an inter-
action hub for other proteins (167). Introduction of stable
negative charges by replacement of up to eight R domain
PKA target serines with aspartates (199) or glutamates (4,
18) resulted in a small, but substantial, activity before ex-
posure to exogenous PKA, although some part of that small
activity might have reflected basal phosphorylation of re-
maining serines by endogenous kinases. In any case, given
FIGURE 6. Regulation of CFTR channel activity through phosphory-
lation by PKA. A: Time course of phosphorylation of an R domain
peptide [amino acid position (a.a.) 645–835] by PKA resolved by SDS/
PAGE. Autoradiogram shows samples incubated for the indicated time
intervals in 1 or 50 M (as indicated) [32P]-ATP and 0.2 g/ml PKA
catalytic subunit. Six distinct resolvable bands are numbered. B: Inside-
out patch recording showing activity of four WT CFTR channels ex-
posed to 55 and then 550 nM PKA catalytic subunit in the presence of
2 mM Mg-ATP; Vm  40 mV. C: Steady-state open probability of WT
(red symbols) and S768A (blue symbols) CFTR channels gating in 2
mM ATP and various concentrations of PKA catalytic subunit, plotted
as a function of [PKA]. Solid lines are fits to the Hill equation; Po,max 
0.34 
 0.06, K0.5  149 
 46 nM, and nH  1.5 
 0.5 for WT
and Po,max  0.51 
 0.05, K0.5 71 
 12 nM, and nH 1.8 
0.5
for S768A.D: Macroscopic CFTR current elicited in an inside-out patch
by exposure to 2 mM Mg-ATP (gray bar) and 300 nM PKA catalytic
subunit (black bar); Vm  80 mV. Activation time course is fitted (red
line) to a sequential two-step mechanism of the form closed¡
closed¡active. E: Cartoon model of two-step channel activation; color
coding as in FIGURE 2E; R domain, red tongue; D, dephosphorylated;
P, phosphorylatable; M, maximally phosphorylated. Occasional sponta-
neous release of the unphosphorylated regulatory (R) domain (step
D¡P) allows its phosphorylation by PKA (step P¡M). [Adapted with
permission from Csanády et al. (58) (A–C) and Liu et al. (145) (D–E )].
CFTR ANION CHANNEL
727Physiol Rev • VOL 99 • JANUARY 2019 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (193.224.049.128) on January 15, 2019.
the existence of both inhibitory and stimulatory sites, mere
accumulation of negative charge in the R domain is unlikely
to explain channel activation by phosphorylation; rather,
conformational changes must also play a role.
Several mechanisms of phosphorylation-dependent regula-
tion of CFTR gating had been proposed in the past. The
unphosphorylated R domain was suggested to act as a plug
that physically occludes the pore (199, 200). Phosphoryla-
tion was suggested to increase the affinity of ATP for bind-
ing to the NBDs (131, 154, 262). Prompted by their spatial
positioning and high mobilities in the NBD1 structure, as
well as their inclusion of phosphorylatable serines, the RI
and RE segments were suggested to impede NBD dimeriza-
tion while unphosphorylated (130). However, split RI
CFTR channels lacking residues 415–432, as well as split
RE channels lacking residues 634–667, and RE chan-
nels with the only phosphorylatable serine in the RI mu-
tated (RE/S422A) all retained unaltered, strict PKA-de-
pendence of channel activity (54). Moreover, even the low-
level ATP-independent activity of CFTR channels with the
entire NBD2 domain (a.a. 1198–1480) deleted (NBD2)
remains fully dependent on phosphorylation by PKA, sug-
gesting that the R domain exerts its modulatory effect by
acting directly on the TMD extensions (248). Finally, be-
cause phosphorylation little affected [32P]8-azido-ATP la-
beling of NBD1, or of NBD2, in the presence of Vi, phos-
phorylation was suggested to modulate coupling between
ATP hydrolysis cycles and gating movements, similar to an
automobile clutch (14).
A recent breakthrough toward a clear mechanistic picture
has come with the first high-resolution structures of un-
phosphorylated CFTR (145, 273). Although in those struc-
tures the R domain is not well resolved, consistent with the
suggested lack of a well-defined structure, its clearly visible
density is wedged in between the two NBDs and among the
cytosolic extensions of the TM helices. Such an arrange-
ment is sterically incompatible both with a transition to an
outward-facing TMD conformation and with NBD
dimerization, explaining the inhibitory effect of the unphos-
phorylated R domain on channel gating. A single resolvable
-helix wedged in between the TM helices, believed to cor-
respond to residues 825–843 of the R domain (FIGURE 1E,
yellow surface plot), is likely important for inhibition, as
severing that helix by coexpression of CFTR segments
1–835 and 837–1480 results in channels that display sub-
stantial phosphorylation-independent channel activity (55).
In light of the occluded localization of the unphosphory-
lated R domain (cartooned as a red tongue in FIGURE 6E),
how does PKA gain access to its target serines? Possibly,
occasional spontaneous release of the unphosphorylated R
domain peptide from its occluded position (FIGURE 6E, left;
D  dephosphorylated) renders it accessible to the kinase
(FIGURE 6E, center; P phosphorylatable) which, by phos-
phorylating its serines, traps the R domain in its released
conformational ensemble (FIGURE 6E, right; M  maxi-
mally phosphorylated), no longer incompatible with an
outward-facing (open-pore) TMD conformation. Consis-
tent with occasional release of the unphosphorylated R do-
main, dephosphorylated CFTR protein displays a small, but
measurable, ATPase activity (131, 145), and, also in the
presence of ATP, unphosphorylated CFTR channels are
seen to gate with a small, but discernible, open probability
[FIGURE 6D, inset (145)]; neither process is compatible with
the wedged-in position of the R domain seen in the unphos-
phorylated structures. Moreover, the time course of macro-
scopic CFTR current activation upon exposure to PKA is
clearly sigmoidal (FIGURE 6D) and can be reasonably well
fitted assuming two sequential slow steps in the activation
process (FIGURE 6D, red curve): the slowest step might re-
flect the spontaneous R domain release (FIGURE 6E, step
D¡P, rate ka1) and the subsequent step, R domain phos-
phorylation (FIGURE 6E, step P¡M, rate ka2).
Open questions remain. It is still unclear whether, in un-
phosphorylated CFTR, ATP hydrolysis might happen with-
out concomitant pore opening, as implied by the automo-
bile clutch model. On the one hand, based on the available
structures, it is unclear howNBDdimerization (required for
ATP hydrolysis) might occur without concomitant pore
opening. But, on the other hand, although phosphorylation
clearly robustly stimulates ATPase activity, the 8- (145) to
15-fold (131) difference in ATPase rates measured for PKA-
versus phosphatase-treated–purified CFTR protein seems
to fall short of explaining the ~100-fold stimulation of
channel currents upon PKA exposure [FIGURE 6D (54)],
unless specific gating changes are invoked. Possibly, some of
the basal ATPase activity measured for dephosphorylated
CFTRmight reflect a minute contamination by some highly
active ATPase; given the turnover rate of ~1 s1 for CFTR,
but up to ~1000 s1 for many other ATPases, a 0.01%
contamination of a CFTR protein preparation by such an
ATPase might account for a basal activity ~10% of that of
phosphorylated CFTR, possibly contributing to the much
lower apparent stimulation of ATPase than of channel ac-
tivity by phosphorylation. A further uncertainty is the
mechanism of the approximately twofold stimulation of
channel open probability by the phosphorylated R domain,
an action apparently distinct from the ~50-fold stimulation
that results from the disinhibitory effect of phosphorylat-
ing, or deleting, the R domain. Kinetic analysis suggests the
approximately twofold stimulation reflects in part slowing
of channel closure (55), but the absence of any density for
the R domain in the cryo-EM structure of phosphorylated
CFTR precludes speculation as to how that might occur.
VI. TARGETING CFTR FUNCTION TO TREAT
DISEASE
Although for decades the treatment of CF has largely fo-
cused on treating the symptoms of the disease, in recent
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years, new drugs have emerged that directly bind to CFTR
and so target the primary molecular defect. Potentiators are
small molecules that enhance CFTR open probability, thus
offering hope to restore channel activity decreased by Class
III (and IV) CF mutations. In contrast, pharmacological
agents aimed at amending the protein folding/processing
defect caused by Class II CF mutations are called “correc-
tors.” Because the most common CF mutation, F508, be-
longs to both classes, effective treatment of the majority of
CF patients will likely require a viable combination of cor-
rector and potentiator drugs. The following paragraphs
provide a brief overview of what is known about how pres-
ently available potentiators work.
The feasibility of designing practically useful potentiators
was signaled by early identification of a number of com-
pounds that stimulate CFTR channel gating when applied
in vitro. Replacement of ATP with various analogs such as
P-ATP (280), 2=- and 3=-deoxy-ATP (3) and 2=-deoxy-P-
ATP (161) increases open probability for WT CFTR and
even more so for mutants with low open probabilities. The
structurally unrelated natural plant compounds genistein
(105, 247), capsaicin (2), and curcumin (19, 248) were
shown to increase CFTR activity with apparent affinities in
the tens-of-micromolar range. All three compounds act by
simultaneously speeding channel opening and delaying
channel closure and likely share overlapping binding sites,
as the effects of genistein and capsaicin (2), or of genistein
and curcumin (19), are competitive. The negatively charged
voltage-dependent pore blocker NPPB (276) was later
found to strongly potentiate channel open probability, and
this potentiator effect was retained, without pore block, in
the uncharged amide analog NPPB-AM (250). NPPB simi-
larly increases the rates of opening and of nonhydrolytic
closure of WT CFTR (59), suggesting that it decreases the
energetic barrier for the C1↔O1 step (FIGURE 2E); interest-
ingly, thanks to CFTR’s nonequilibrium gating cycle, such a
catalyst effect might enhance opening rate without speeding
normal (hydrolytic) closure. In fact, NPPB also slows hy-
drolytic channel closing rate by slowing the ATP hydrolysis
step [FIGURE 2E, step O1¡O2 (59)]. These two distinct
kinetic effects can be ascribed, respectively, to the 3-nitro-
benzoate and 3-phenylpropylamine moieties of the parent
compound (60). In addition, NPPB also increases open
probability of the G551D mutant (134), which opens pref-
erentially with site 2 vacant (133), suggesting that it might
either stabilize the monoliganded open state more than the
transition state for the C1↔O1 step or stabilize only the
monoliganded open state in the mutant.
The first potentiator evaluated in clinical trials was VX-770
(ivacaftor), identified by Vertex Pharmaceuticals using
high-throughput screening. VX-770 very effectively stimu-
lates CFTR channels carrying the common Class III muta-
tion G551D (~2% of CF alleles), but was also found to
enhance F508 CFTR activity in vitro (238). Later work
demonstrated the drug’s efficacy on a number of other less
frequent Class III (and Class IV) mutants (267). At present,
the drug is approved in most Western countries for the
treatment of CF patients carrying G551D and some other
rare mutant alleles, all of which strongly impact gating. In
vitro mechanistic studies of VX-770 action revealed current
stimulation for both WT CFTR and for nonhydrolytic mu-
tants. Kinetically, VX-770 acts by increasing channel open-
ing rate and by slowing both hydrolytic and nonhydrolytic
closing rate (112, 125, 134). Althoughmore complexmech-
anisms have been suggested [see Section IVE (112)], the
simplest explanation of these kinetic effects is a stabilization
of state O1 (relative to both C1 and O2; FIGURE 2E) by the
drug; just as for the binding of ATP itself (see Section IVF),
VX-770 stabilizes the transition state (T, FIGURE 3B) for
opening (modestly increasing rate kCO), but stabilizes state
O1 even more (decreasing rate k1). Insofar as the rarely
visited unliganded open state of CFTR is structurally simi-
lar to state O1 [see Section IVD (160)], such a mechanism
would also explain the observed stimulation by VX-770 of
spontaneous channel activity in the absence of ATP (74,
112). Similar fold potentiation of nonhydrolytic mutants,
K464A CFTR, and WT CFTR channels, which visit the
posthydrolytic state O2 in none, in a small proportion, or in
all of the open-burst events, respectively, suggests that any
effect on stability of the posthydrolytic state O2 (112) is
likely to be minor (126). Consistent with its extremely hy-
drophobic nature (logP, ~6.3) the binding site for VX-770 is
believed to be located in the membrane-spanning region of
CFTR (112).
The clinical success of administering VX-770 in combina-
tion with corrector compounds to treat patients carrying
F508 alleles has, so far, been limited (244). This disap-
pointing result might be due to a demonstrated negative
impact of VX-770 on F508 CFTR biogenesis, and partic-
ularly on its stability at the plasma membrane. Thus, the
potentiator appears to effectively counteract the action of
coadministered corrector drugs, VX-809 (lumacaftor), and
VX-661 (45, 240). Surprisingly, a number of structurally
diverse potentiators were found to cause a similar reduction
in F508 CFTR plasma membrane density (240). As men-
tioned above, F508 is positioned at the transmission inter-
face that connects the TMDs andNBD1 on the outer side of
the “socket” in which CH4 (the “ball” element of the joint,
see Section IIC) fits. A conserved, short -helix completes
the socket in most ABC proteinNBDs (see FIGURE 1B, green
helix in NBD2) but is absent from CFTR’s NBD1. It is
possible that the reduced metabolic stability of potentiator-
bound F508 CFTR at the plasma membrane might result
from the increased frequency of opening, and hence in-
creased exposure of the fragile mutant, lacking the socket-
completing phenylalanine, to the high molecular strain of
the opening transition state [(6, 57, 155), see Section IVC].
Consistent with this interpretation, mutations, such as
E1371S, that decrease the frequency of pore-opening events
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by greatly prolonging burst duration, were seen to protect
F508 CFTR from VX-770–induced peripheral instability
(240). These considerations suggest that potentiators that
increase burst duration, and/or strongly reduce the strain in
the opening transition state (59, 60), might be better suited
for treatment of patients carrying the F508 mutation.
Given the very large number of CFTR mutations known to
cause CF, this observation highlights how precision poten-
tiator development might need to be tailored according to
the CFTR genotype, as potentiators developed for potency/
efficacy on F508 CFTR might not provide maximal ther-
apeutic benefit to all CF patients.
Recently, the potentiator GLPG1837, developed by Ab-
bvie–Galapagos, has also entered clinical trials. Although
GLPG1837 was found to be more effective on G551D and
G1349D CFTR than VX-770, the mechanisms of action of
the two drugs seem similar; indeed, GLPG1837 also poten-
tiates both WT CFTR and nonhydrolytic mutants and acts
by speeding channel opening and by slowing both hydro-
lytic and nonhydrolytic pore closure (265). Thus, just as for
VX-770, a plausible mechanism for GLPG1837 might be
stabilization of state O1 relative to C1, O2 (FIGURE 2E), and
T (FIGURE 3B). In linewith such an explanation, GLPG1837
also stimulates spontaneous CFTR opening (265). In con-
trast to NPPB, which acts synergistically with VX-770, sug-
gesting distinct binding sites, GLPG1837 and VX-770 act
competitively, suggesting that binding of these two drugs is
mutually exclusive (i.e., that their binding sites might over-
lap) (265).
Several additional laboratories are actively involved in
CFTR potentiator development. Employing high-through-
put screening, the Verkman group was the first to identify
potentiators with low micromolar (84) or submicromolar
(152, 180) affinities based on a variety of structurally unre-
lated chemical scaffolds. Furthermore, some of their re-
cently identified potentiators have been shown not to re-
duce plasma membrane density of F508 CFTR or to inter-
fere with the corrector effect of VX-809 and are,
therefore, promising candidates for CF therapy of pa-
tients carrying F508, or similar phenotype alleles (182).
Other groups have identified potential lead compounds
capable of increasing CFTR open probability [(79,
127, 179), https://www.cff.org/Trials/Pipeline/details/91/
QBW251]. However, so far, the mechanisms of action of all
these compounds have not been studied in detail.
The recognition that CFTR plays a vital physiological role
in regulating transepithelial fluid movement has prompted
researchers to start considering it as a pharmacological tar-
get for treatment of disorders other than CF. Potentiators
might be useful for the treatment of other airway diseases
sharing characteristics with CF, such as mucus stasis and
CFTR dysfunction/inhibition. One such area of clinical in-
terest is the treatment of chronic obstructive pulmonary
disease (191, 214). Focusing, instead, on CFTR expressed
in intestinal epithelia, initial results suggest CFTR potenti-
ators can outperform currently approved treatments for
constipation (47, 217).
In contrast, CFTR inhibitors might provide benefit in dis-
eases characterized by excessive transepithelial fluid move-
ment. Such compounds could help prevent cyst formation
in autosomal dominant polycystic kidney disease (132,
263) and could be crucial in preventing death by dehydra-
tion caused by secretory diarrheas (e.g., following cholera
infection), especially in situations in which obtaining safe
water for oral rehydration therapy is problematic (229).
The voltage-dependent pore blocker GlyH-101 that acts
from outside the cell has been described (Section IIID).
CFTRinh-172 (3-[(3-trifluoromethyl)phenyl]-5-[(4-car-
boxyphenyl)methylene]-2-thioxo-4-thiazolidinone) was
identified by high-throughput screening as a membrane-
permeant compound that inhibits CFTR currents in a volt-
age-independent manner with aKI of ~300 nM (151). Stud-
ies addressing the mechanism of this inhibition concluded
that CFTRinh-172 does not act as a pore blocker, but rather
as a gating modifier that delays pore opening and acceler-
ates pore closure (124, 228). More recently, higher-potency
benzopyrimido-pyrrolo-oxazinedione compounds have
been identified that bind at site 2 in competition with ATP,
thus impeding channel opening (118). The nanomolar po-
tency attained with these compounds might make such
drugs specific enough to avoid short-term toxicity at non-
target ATP binding sites.
VII. CONCLUDING REMARKS
Almost three decades after the cloning of the CFTR gene,
our understanding of CFTR structure and function has seen
tremendous progress; meanwhile, high-throughput screen-
ing has led to the development of potentiator and corrector
drugs that are finding their way to clinical application.
There are undoubtedly still major gaps in our knowledge
that need to be filled. These include unraveling what an
open channel looks like and what state the outward-facing
zebrafish CFTR structure represents, clarifying the exis-
tence and functional significance of reentry events, deter-
mining the extent of interface separation in the degenerate
site of closed channels during gating, dissecting possible
conformations of the R domain and their dependence on
phosphorylation, and mapping protein/protein interactions
of CFTR with scaffolding proteins and with other channels
and transporters. That notwithstanding, with the recent
breakthrough provided by the first high-resolution struc-
tures, CFTR research has transitioned into a new era, one
that holds the promise of exploiting atomic-level structural
information and advances in mechanistic understanding of
CFTR molecular motions to guide drug development.
There is now well-grounded hope that decades of basic
research could soon strongly impact human health, result-
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ing in novel treatments for a variety of disorders and an
effective causative treatment for both common and rare
forms of CF.
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